

## 6. References

- Adami, H.-O., Persson, I., Hoover, R., Schairer, C. & Bergkvist, L. (1989) Risk of cancer in women receiving hormone replacement therapy. *Int. J. Cancer*, **44**, 833–839
- Adami, H.-O., Bergström, R., Persson, I. & Sparén, P. (1990) The incidence of ovarian cancer in Sweden, 1960–1984. *Am. J. Epidemiol.*, **132**, 446–452
- Adams, J.B., Hall, R.T. & Nott, S. (1986) Esterification–deesterification of estradiol by human mammary cancer cells in culture. *J. Steroid Biochem.*, **24**, 1159–1162
- Aedo, A.-R., Landgren, B.-M. & Diczfalusy, E. (1990) Pharmacokinetics and biotransformation of orally administered oestrone sulphate and oestradiol valerate in post-menopausal women. *Maturitas*, **12**, 333–343
- Alexander, F.E., Roberts, M.M. & Huggins, A. (1987) Risk factors for breast cancer with applications to selection for the prevalence screen. *J. Epidemiol. Community Health*, **41**, 101–106
- American College of Physicians (1992) Guidelines for counseling postmenopausal women about preventive hormone therapy. *Ann. intern. Med.*, **117**, 1038–1041
- Anderson, F. (1993) Kinetics and pharmacology of estrogens in pre- and postmenopausal women. *Int. J. Fertil.*, **38** (Suppl. 1), 53–64
- Anon. (1996) Hormone replacement therapy. *Drugs Ther. Bull.*, **34**, 81–84
- Ansbacher, R. (1993) Bioequivalence of conjugated estrogen products. *Clin. Pharmacokinet.*, **24**, 271–274
- Antunes, C.M.F., Stolley, P.D., Rosenshein, N.B., Davies, J.L., Tonascia, J.A., Brown, C., Burnett, L., Rutledge, A., Pokempner, M. & Garcia, R. (1979) Endometrial cancer and estrogen use. Report of a large case–control study. *New Engl. J. Med.*, **300**, 9–13
- Armstrong, B.K. & Kricker, A. (1994) Cutaneous melanoma. *Cancer Surv.*, **19**, 219–240
- Arrick, B.A., Korc, M. & Derynck, R. (1990) Differential regulation of expression of three transforming growth factor  $\beta$  species in human breast cancer cell lines by estradiol. *Cancer Res.*, **50**, 299–303

- Austin, D.F. & Roe, K.M. (1982) The decreasing incidence of endometrial cancer: Public health implications. *Am. J. public Health*, **72**, 65–68
- Balfour, J.A. & Heel, R.C. (1990) Transdermal estradiol: A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the treatment of menopausal complaints. *Drugs*, **40**, 561–582
- Banduhn, N. & Obe, G. (1985) Mutagenicity of methyl 2-benzimidazolecarbamate, diethylstilbestrol and estradiol: Structural chromosomal aberrations, sister-chromatid exchanges, C-mitoses, polyploidies and micronuclei. *Mutat. Res.*, **156**, 199–218
- Banerjee, S.K., Banerjee, S., Li, S.A. & Li, J.J. (1994) Induction of chromosome aberrations in Syrian hamster renal cortical cells by various estrogens. *Mutat. Res.*, **311**, 191–197
- Banks, E., Crossley, B., English, R. & Richardson, A. (1996) Women doctors' use of hormone replacement therapy: High prevalence of use is not confined to doctors (Letter to the Editor). *Br. med. J.*, **312**, 638
- Barrett-Connor, E.L., Brown, W.V., Turner, J., Austin, M. & Criqui, M.H. (1979) Heart disease risk factors and hormone use in postmenopausal women. *J. Am. med. Assoc.*, **241**, 2167–2169
- Barrett-Connor, E.L., Wingard, D.L. & Criqui, M.H. (1989) Postmenopausal estrogen use and heart disease risk factors in the 1980s. *J. Am. med. Assoc.*, **261**, 2095–2100
- Batra, S., Bjork, P. & Sjogren, C. (1984) Binding of estradiol-17 beta and estriol in cytosolic and nuclear fractions from urogenital tissues. *J. Steroid Biochem.*, **21**, 163–168
- Bauss, F., Esswein, A., Reiff, K., Sponer, G. & Müller-Beckmann, B. (1996) Effect of 17 $\beta$ -estradiol-bisphosphonate conjugates, potential bone-seeking estrogen pro-drugs, on 17 $\beta$ -estradiol serum kinetics and bone mass in rats. *Calcified Tissue int.*, **59**, 168–173
- Bawarshi-Nassar, R.N., Hussain, A.A. & Crooks, P.A. (1989) Nasal absorption and metabolism of progesterone and 17 beta-estradiol in the rat. *Drug Metab. Disposition*, **17**, 248–254
- Beral, V., Evans, S., Shaw, H. & Milton, G. (1984) Oral contraceptive use and malignant melanoma in Australia. *Br. J. Cancer*, **50**, 681–685
- Beresford, S.A.A., Weiss, N.S., Voigt, L.F. & McKnight, B. (1997) Risk of endometrial cancer in relation to use of oestrogen combined with cyclic progestagen therapy in postmenopausal women. *Lancet*, **349**, 458–461
- Bergkvist, L., Adami, H.-O., Persson, I., Hoover, R. & Schairer, C. (1989) The risk of breast cancer after estrogen and estrogen-progestin replacement. *New Engl. J. Med.*, **321**, 293–297
- Bhavnani, B.R. (1998) Pharmacokinetics and pharmacodynamics of conjugated equine estrogens: Chemistry and metabolism. *Proc. Soc. exp. Med. Biol.*, **217**, 6–16
- Bhavnani, B.R. & Woolever, C.A. (1991) Interaction of ring B unsaturated estrogens with estrogen receptors of human endometrium and rat uterus. *Steroids*, **56**, 201–210
- Bidmon, H.J., Pitts, J.D., Solomon, H.F., Bondi, J.V. & Stumpf, W.E. (1990) Estradiol distribution and penetration in the rat skin after topical application, studied by high resolution autoradiography. *Histochemistry*, **95**, 43–54
- Bishop, P.M.F. (1938) A clinical experiment in oestrin therapy. *Br. med. J.*, **i**, 939–941
- Bolt, H.M. (1979) Metabolism of estrogens—natural and synthetic. *Pharmacol. Ther.*, **4**, 155–181
- Booth, M., Beral, V. & Smith, P. (1989) Risk factors for ovarian cancer: A case-control study. *Br. J. Cancer*, **60**, 592–598

- Bostick, R.M., Potter, J.D., Kushi, L.H., Sellers, T.A., Steinmetz, K.A., McKenzie, D.R., Gapstur, S.M. & Folsom, A.R. (1994) Sugar, meat, and fat intake, and non-dietary risk factors for colon cancer incidence in Iowa women (United States). *Cancer Causes Control*, **5**, 38–52
- Botella, J., Duranti, E., Viader, V., Duc, I., Delansorne, R. & Paris, J. (1995) Lack of estrogenic potential of progesterone- or 19-nor-progesterone-derived progestins as opposed to testosterone or 19-nortestosterone derivatives on endometrial Ishikawa cells. *J. Steroid Biochem. mol. Biol.*, **55**, 77–84
- Boyd, J. (1996) Estrogen as a carcinogen: The genetics and molecular biology of human endometrial carcinoma. In: Huff, J., Boyd, J. & Barrett, J.C., eds, *Cellular and Molecular Mechanisms of Hormonal Carcinogenesis: Environmental Influences*, New York, Wiley-Liss, pp. 151–173
- Brett, K.M. & Madans, J.H. (1997) Use of postmenopausal hormone replacement therapy: Estimates from a nationally representative cohort study. *Am. J. Epidemiol.*, **145**, 536–545
- Brinton, L.A. (1997) Hormone replacement therapy and risk for breast cancer. *Endocrinol. Metab. Clin. N. Am.*, **26**, 361–378
- Brinton, L.A., Hoover, R.N., Szklo, M. & Fraumeni, J.F., Jr (1981) Menopausal estrogen use and risk of breast cancer. *Cancer*, **47**, 2517–2522
- Brinton, L.A., Hoover, R. & Fraumeni, J.F., Jr (1986) Menopausal oestrogens and breast cancer risk: An expanded case–control study. *Br. J. Cancer*, **54**, 825–832
- Brinton, L.A., Hoover, R.N. & the Endometrial Cancer Collaborative Group (1993) Estrogen replacement therapy and endometrial cancer risk: Unresolved issues. *Obstet. Gynecol.*, **81**, 265–271
- Brinton, L.A., Dalling, J.R., Liff, J.M., Schoenberg, J.B., Malone, K.E., Stanford, J.L., Coates, R.J., Gammon, M.D., Hanson, L. & Hoover, R.N. (1995) Oral contraceptives and breast cancer risk among younger women. *J. natl Cancer Inst.*, **87**, 827–835
- British Medical Association (1997) *British National Formulary*, No. 34, London, Royal Pharmaceutical Society of Great Britain, pp. 345–349
- Brown, A.M.C., Jeltsch, J.-M., Roberts, M. & Chambon, P. (1984) Activation of *p52* gene transcription is a primary response to estrogen in the human breast cancer cell line MCF-7. *Proc. natl Acad. Sci. USA*, **81**, 6344–6348
- Buring, J.E., Bain, C.J. & Ehrmann, R.L. (1986) Conjugated estrogen use and risk of endometrial cancer. *Am. J. Epidemiol.*, **124**, 434–441
- Buring, J.E., Hennekens, C.H., Lipnick, R.J., Willett, W., Stampfer, M.J., Rosner, B., Peto, R. & Speizer, F.E. (1987) A prospective cohort study of postmenopausal hormone use and risk of breast cancer in US women. *Am. J. Epidemiol.*, **125**, 939–947
- Bush, T.L. & Barrett-Connor, E. (1985) Noncontraceptive estrogen use and cardiovascular disease. *Epidemiol. Rev.*, **7**, 80–104
- Calle, E.E., Miracle-McMahill, H.L., Thun, M.J. & Heath, C.W., Jr (1995) Estrogen replacement therapy and risk of fatal colon cancer in a prospective cohort of postmenopausal women. *J. natl Cancer Inst.*, **87**, 517–523

- Campagnoli, C., Biglia, N., Altare, F., Lanza, M.G., Lesca, L., Cantamessa, C., Peris, C., Fiorucci, G.C. & Sismondi, P. (1993) Differential effects of oral conjugated estrogens and transdermal estradiol on insulin-like growth factor 1, growth hormone and sex hormone binding globulin serum levels. *Gynecol. Endocrinol.*, **7**, 251–258
- Campbell, A.D. & Collip, J.B. (1930) Notes on the clinical use of certain placental extracts. *Can. med. Assoc. J.*, **23**, 633–641
- Catherino, W.H. & Jordan, V.C. (1995) Nomegestrol acetate, a clinically useful 19-norprogesterone derivative which lacks estrogenic activity. *J. Steroid Biochem. mol. Biol.*, **55**, 239–246
- Cauley, J.A., Cummings, S.R., Black, D.M., Mascioli, S.R. & Seeley, D.G. (1990) Prevalence and determinants of estrogen replacement therapy in elderly women. *Am. J. Obstet. Gynecol.*, **163**, 1438–1444
- Cavaliere, E.L., Stack, D.E., Devanesan, P.D., Todorovic, R., Dwivedy, I., Higginbotham, S., Johansson, S.L., Patil, K.D., Gross, M.L., Gooden, J.K., Ramanathan, R., Cerny, R.L. & Rogan, E.G. (1997) Molecular origin of cancer: Catechol estrogen-3,4-quinones as endogenous tumour initiators. *Proc. natl Acad. Sci. USA*, **94**, 10937–10942
- Caviezel, M., Lutz, W.K. & Minini, C. (1984) Interaction of estrone and estradiol with DNA and protein of liver and kidney in rat and hamster *in vivo* and *in vitro*. *Arch. Toxicol.*, **55**, 97–103
- Celli, G., Darwiche, N. & De Luca, L.M. (1996) Estrogen induces retinoid receptor expression in mouse cervical epithelia. *Exp. Cell Res.*, **226**, 273–282
- Chandrasekaran, A., Osman, M., Scatina, J.A. & Sisenwine, S.F. (1995) Metabolism of equilin sulfate in the dog. *J. Steroid Biochem. mol. Biol.*, **55**, 271–278
- Chanez, J.F., de Lignières, B., Marty, J.P. & Wepierre, J. (1989) Influence of the size of the area of treatment on percutaneous absorption of estradiol in the rat. *Skin Pharmacol.*, **2**, 15–21
- Chen, M.J., Longnecker, M.P., Morgenstern, H., Lee, E.R., Frankl, H.D. & Haile, R.W. (1998) Recent use of hormone replacement therapy and the prevalence of colorectal adenomas. *Cancer Epidemiol. Biomarkers Prev.*, **7**, 227–230
- Chow, W.-H., McLaughlin, J.K., Mandel, J.S., Blot, W.J., Niwa, S. & Fraumeni, J.F., Jr (1995) Reproductive factors and the risk of renal cell cancer among women. *Int. J. Cancer*, **60**, 321–324
- Chute, C.G., Willett, W.C., Colditz, G.A., Stampfer, M.J., Rosner, B. & Speizer, F.E. (1991) A prospective study of reproductive history and exogenous estrogens on the risk of colorectal cancer in women. *Epidemiology*, **2**, 201–207
- Cline, J.M., Soderqvist, G., von Schoultz, E., Skoog, L. & von Schoultz, B. (1996) Effects of hormone replacement therapy on the mammary gland of surgically postmenopausal cynomolgus macaques. *Am. J. Obstet. Gynecol.*, **174**, 93–100
- Coldham, N.G. & James, V.H.T. (1990) A possible mechanism for increased breast cell proliferation by progestins through increased reductive 17 $\beta$ -hydroxysteroid dehydrogenase activity. *Int. J. Cancer*, **45**, 174–178
- Colditz, G.A. (1996) Postmenopausal estrogens and breast cancer. *J. Soc. gynecol. Invest.*, **3**, 50–56

- Colditz, G.A., Stampfer, M.J., Willett, W.C., Hunter, D.J., Manson, J.E., Hennekens, C.H., Rosner, B.A. & Speizer, F.E. (1992) Type of postmenopausal hormone use and risk of breast cancer: 12-year follow-up from the Nurses' Health Study. *Cancer Causes Control*, **3**, 433–439
- Colditz, G.A., Hankinson, S.E., Hunter, D.J., Willett, W.C., Manson, J.E., Stampfer, M.J., Hennekens, C.H., Rosner, B.A. & Speizer, F.E. (1995) The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. *New Engl. J. Med.*, **332**, 1589–1593
- Collaborative Group on Hormonal Factors in Breast Cancer (1997) Breast cancer and hormone replacement therapy: Collaborative reanalysis of data from 51 epidemiological studies of 52 705 women with breast cancer and 108 411 women without breast cancer. *Lancet*, **350**, 1047–1059
- Cushing, K.L., Weiss, N.S., Voigt, L.F., McKnight, B. & Beresford, S.A.A. (1998) Risk of endometrial cancer in relation to use of low-dose, unopposed estrogens. *Obstet. Gynecol.*, **91**, 35–39
- Das, P., Rao, A.R. & Srivastava, P.N. (1988) Modulatory influences of exogenous estrogen on MCA-induced carcinogenesis in the uterine cervix of mouse. *Cancer Lett.*, **43**, 73–77
- Davis, F.G., Furner, S.E., Persky, V. & Koch, M. (1989) The influence of parity and exogenous female hormones on the risk of colorectal cancer. *Int. J. Cancer*, **43**, 587–590
- Derby, C.A., Hume, A.L., Barbour, M.M., McPhillips, J.B., Lasater, T.M. & Carleton, R.A. (1993) Correlates of postmenopausal estrogen use and trends through the 1980s in two southeastern New England communities. *Am. J. Epidemiol.*, **137**, 1125–1135
- Devesa, S.S., Silverman, D.T., Young, J.L., Jr, Pollack, E.S., Brown, C.C., Horm, J.W., Percy, C.L., Myers, M.H., McKay, F.W. & Fraumeni, J.F., Jr (1987) Cancer incidence and mortality trends among whites in the United States, 1947–84. *J. natl Cancer Inst.*, **79**, 701–770
- Drevon, C., Piccoli, C. & Montesano, R. (1981) Mutagenicity assays of estrogenic hormones in mammalian cells. *Mutat. Res.*, **89**, 83–90
- Duval, D., Durant, S. & Homo-Delarche, F. (1983) Non-genomic effects of steroids: Interactions of steroid molecules with membrane structures and functions. *Biochim. biophys. Acta*, **737**, 409–442
- Egeland, G.M., Matthews, K.A., Kuller, L.H. & Kelsey, S.F. (1988) Characteristics of non-contraceptive hormone users. *Prev. Med.*, **17**, 403–411
- El-Bayoumy, K., Ji, B.-Y., Upadhyaya, P., Chac, Y.-H., Kurtzke, C., Riverson, A., Reddy, B.S., Amin, S. & Hecht, S.S. (1996) Lack of tumorigenicity of cholesterol epoxides and estrone-3,4-quinone in the rat mammary gland. *Cancer Res.*, **56**, 1970–1973
- Ettinger, B., Golditch, I.M. & Friedman, G. (1988) Gynecologic consequences of long-term, unopposed estrogen replacement therapy. *Maturitas*, **10**, 271–282
- Ewertz, M. (1988) Influence of non-contraceptive exogenous and endogenous sex hormones on breast cancer risk in Denmark. *Int. J. Cancer*, **42**, 832–838
- Ewertz, M., Machado, S.G., Boice, J.D. & Jensen, O.M. (1984) Endometrial cancer following treatment for breast cancer: A case-control study in Denmark. *Br. J. Cancer*, **50**, 687–692
- Ewertz, M., Schou, G. & Boice, J.D. (1988) The joint effect of risk factors on endometrial cancer. *Eur. J. Cancer clin. Oncol.*, **24**, 189–194

- Fernandez, E., La Vecchia, C., D'Avanzo, B., Franceschi, S., Negri E. & Parazzini, F. (1996) Oral contraceptives, hormone replacement therapy and the risk of colorectal cancer. *Br. J. Cancer*, **73**, 1431–1435
- Fernandez, E., La Vecchia, C., Braga, C., Talamini, R., Negri, E., Parazzini, F. & Franceschi, S. (1998) Hormone replacement therapy and risk of colon and rectal cancer. *Cancer Epidemiol. Biomarkers Prev.*, **7**, 329–333
- Finkle, W.D., Greenland, S., Miettinen, O.S. & Ziel, H.K. (1995) Endometrial cancer risk after discontinuing use of unopposed conjugated estrogens (California, United States). *Cancer Causes Control*, **6**, 99–102
- Finnegan, L.P., Rossouw, J. & Harlan, W.R. (1995) A peppy response to PEPI results. *Nature Med.*, **1**, 205–206
- Folsom, A.R., Mink, P.J., Sellers, T.A., Hong, C.P., Zheng, W. & Potter, J.D. (1995) Hormonal replacement therapy and morbidity and mortality in a prospective study of postmenopausal women. *Am. J. public Health*, **85**, 1128–1132
- Forsberg, J.G. (1991) Estrogen effects on chromosome number and sister chromatid exchanges in uterine epithelial cells and kidney cells from neonatal mice. *Teratog. Carcinog. Mutag.*, **11**, 135–146
- Francavilla, A., Polimeno, L. DiLeo, A., Barone, M., Ove, P., Coetzee, M., Eagon, P., Makowka, L., Ambrosino, G., Mazzaferro, V. & Starzl, T.E. (1989) The effect of estrogen and tamoxifen on hepatocyte proliferation *in vivo* and *in vitro*. *Hepatology*, **9**, 614–620
- Franceschi, S. & Dal Maso, L. (1999) Hormonal imbalance and thyroid cancers in humans. In: Capen, C.C., Dybing, E., Rice, J.M. & Wilbourn, J.D., eds, *Species Differences in Thyroid, Kidney and Urinary Bladder Carcinogenesis* (IARC Scientific Publications No. 147), Lyon, IARC, pp. 33–44
- Franceschi, S. & La Vecchia, C. (1994) Thyroid cancer. *Cancer Surv.*, **19**, 393–422
- Franceschi, S., La Vecchia, C., Helmrigh, S.P., Mangioni, C. & Tognoni, G. (1982) Risk factors for epithelial ovarian cancer in Italy. *Am. J. Epidemiol.*, **115**, 714–719
- Franceschi, S., Fassina, A., Talamini, R., Mazzolini, A., Vianello, S., Bidoli, E., Cizza, G. & La Vecchia C. (1990) The influence of reproductive and hormonal factors on thyroid cancer in women. *Rev. Epidémiol. Santé publique*, **38**, 27–34
- Franks, A.L., Kendrick, J.S., Tyler, C.W. & the Cancer and Steroid Hormone Study Group (1987) Postmenopausal smoking, estrogen replacement therapy, and the risk of endometrial cancer. *Am. J. Obstet. Gynecol.*, **156**, 20–23
- Fujimoto, J., Hori, M., Ichigo, S., Morishita, S. & Tamaya, T. (1996a) Estrogen activates migration potential of endometrial cancer cells through basement membrane. *Tumor Biol.*, **17**, 48–57
- Fujimoto, J., Ichigo, S., Hori, M., Morishita, S. & Tamaya, T. (1996b) Progestins and danazol effect on cell-to-cell adhesion, and E-cadherin and  $\alpha$ - and  $\beta$ -catenin mRNA expressions. *J. Steroid Biochem. mol. Biol.*, **57**, 275–282
- Fujimoto, J., Hori, M., Ichigo, S. & Tamaya, T. (1997) Antiestrogenic compounds inhibit estrogen-induced expression of fibroblast growth factor family (FGF-1, 2, and 4) mRNA in well-differentiated endometrial cancer cells. *Eur. J. gynaecol. Oncol.*, **18**, 497–501

- Furner, S.E., Davis, F.G., Nelson, R.L. & Haenszel, W. (1989) A case-control study of large bowel cancer and hormone exposure in women. *Cancer Res.*, **49**, 4936–4940
- Gabrielsson, J., Wallenbeck, I., Larsson, G., Birgerson, L. & Heimer, G. (1995) New kinetic data on estradiol in light of the vaginal ring concept. *Maturitas*, **22** (Suppl.) S35–S39
- Gabrielsson, J., Wallenbeck, I. & Birgerson, L. (1996) Pharmacokinetic data on estradiol in light of the Estring® concept. Estradiol and estring pharmacokinetics. *Acta obstet. gynecol. scand.*, **163** (Suppl.), 26–31
- Galanti, M.R., Hansson, L., Lund, E., Bergström, R., Grimelius, L., Stalsberg, H., Carlsen, E., Baron, J.A., Persson, I. & Ekblom, A. (1996) Reproductive history and cigarette smoking as risk factors for thyroid cancer in women: A population-based case-control study. *Cancer Epidemiol. Biomarkers Prev.*, **5**, 425–431
- Gallagher, R.P., Elwood, J.M., Hill, G.B., Coldman, A.J., Threlfall, W.J. & Spinelli, J.J. (1985) Reproductive factors, oral contraceptives and risk of malignant melanoma: Western Canada melanoma study. *Br. J. Cancer*, **52**, 901–907
- Gambrell, R.D., Jr, Massey, F.M., Castaneda, T.A., Ugenas, A.J., Ricci, C.A. & Wright, J.M. (1980) Use of the progestogen challenge test to reduce the risk of endometrial cancer. *Obstet. Gynecol.*, **55**, 732–738
- Gapstur, S.M., Potter, J.D., Sellers, T.A. & Folsom, A.R. (1992) Increased risk of breast cancer with alcohol consumption in postmenopausal women. *Am. J. Epidemiol.*, **136**, 1221–1231
- Gerhardsson de Verdier, M. & London, S. (1992) Reproductive factors, exogenous female hormones, and colorectal cancer by subsite. *Cancer Causes Control*, **3**, 355–360
- Godfree, V. (1994) Which oestrogen? Does the oestrogen you prescribe as hormone replacement therapy (HRT) make a difference to the patient? *Change*, **4**, 1–2
- Goldfarb, S. & Pugh, T.D. (1990) Morphology and anatomic localization of renal microneoplasms and proximal tubule dysplasias induced by four different estrogens in the hamster. *Cancer Res.*, **50**, 113–119
- Goodman, M.T., Moriwaki, H., Vaeth, M., Akiba, S., Hayabuchi, H. & Mabuchi, K. (1995) Prospective cohort study of risk factors for primary liver cancer in Hiroshima and Nagasaki, Japan. *Epidemiology*, **6**, 36–41
- Goodman, M.T., Cologne, J., Moriwaki, H., Vaeth, M. & Mabuchi, K. (1997a) Risk factors for primary breast cancer in Japan: 8-year follow-up of atomic-bomb survivors. *Prevent. Med.*, **26**, 144–153
- Goodman, M.T., Wilkens, L.R., Hankin, J.H., Lyu, L.-C., Wu, A.H. & Kolonel, L.N. (1997b) Association of soy and fiber consumption with the risk of endometrial cancer. *Am. J. Epidemiol.*, **146**, 294–306
- Gordon, S.F. (1995) Clinical experience with a seven-day estradiol transdermal system for estrogen replacement therapy. *Am. J. Obstet. Gynecol.*, **173**, 998–1004
- Grady, D., Gebretsadik, T., Kerlikowske, K., Ernster, V. & Petitti, D. (1995) Hormone replacement therapy and endometrial cancer risk: A meta-analysis. *Obstet. Gynecol.*, **85**, 304–313
- Gray, L.A., Christopherson, W.M. & Hoover, R.N. (1977) Estrogens and endometrial carcinoma. *Obstet. Gynecol.*, **49**, 385–389

- Green, A. & Bain, C. (1985) Hormonal factors and melanoma in women. *Med. J. Austr.*, **142**, 446–448
- Green, P.K., Weiss, N.S., McKnight, B., Voigt, L.F. & Beresford, S.A.A. (1996) Risk of endometrial cancer following cessation of menopausal hormone use (Washington, United States). *Cancer Causes Control*, **7**, 575–580
- Greene, G.L., Gilna, P., Waterfield, M., Baker, A., Hort, Y. & Shine, J. (1986) Sequence and expression of human estrogen receptor complementary DNA. *Science*, **231**, 1150–1154
- Griffiths, F. & Jones, K. (1995) The use of hormone replacement therapy: Results of a community survey. *Fam. Pract.*, **12**, 163–165
- Grodstein, F., Stampfer, M.J., Colditz, G.A., Willett, W.C., Manson, J.E., Joffe, M., Rosner, B., Fuchs, C., Hankinson, S.E., Hunter, D.J., Hennekens, C.H. & Speizer, F.E. (1997) Postmenopausal hormone therapy and mortality. *New Engl. J. Med.*, **336**, 1769–1775
- Grodstein, F., Martinez, E., Platz, E.A., Giovannucci, E., Colditz, G.A., Kautzky, M., Fuchs, C. & Stampfer, M.J. (1998) Postmenopausal hormone use and risk for colorectal cancer and adenoma. *Ann. intern. Med.*, **128**, 705–712
- Grubbs, C.J., Peckham, J.C. & McDonough, K.D. (1983) Effect of ovarian hormones on the induction of 1-methyl-1-nitrosourea-induced mammary cancer. *Carcinogenesis*, **4**, 495–497
- Grubbs, C.J., Farnell, D.R., Hill, D.L. & McDonough K.C. (1985) Chemoprevention of *N*-nitroso-*N*-methylurea-induced mammary cancers by pretreatment with 17 $\beta$ -estradiol and progesterone. *J. natl Cancer Inst.*, **74**, 927–931
- Gruber, J.S. & Luciani, C.T. (1986) Physicians changing postmenopausal sex hormone prescribing regimens. *Prog. clin. biol. Res.*, **216**, 325–335
- Hajek, R.A., Van, N.T., Johnston, D.A. & Jones, L.A. (1993) In vivo induction of increased DNA ploidy of mouse cervicovaginal epithelium by neonatal estrogen treatment. *Biol. Reprod.*, **49**, 908–917
- Hallquist, A., Hardell, L., Degerman, A. & Boquist, L. (1994) Thyroid cancer: Reproductive factors, previous diseases, drug intake, family history and diet. A case–control study. *Eur. J. Cancer Prev.*, **3**, 481–488
- Hammar, M., Brynhildsen, J., Dabrosin, L., Frisk, J., Lindgren, R., Nedstrand, E. & Wyon, Y. (1996) Hormone replacement therapy and previous use of oral contraceptives among Swedish women. *Maturitas*, **25**, 193–199
- Hammond, C.B., Jelovsek, F.R., Lee, K.L., Creasman, W.T. & Parker, R.T. (1979) Effects of long-term estrogen replacement therapy. II. Neoplasia. *Am. J. Obstet. Gynecol.*, **133**, 537–547
- Han, X. & Liehr, J.G. (1994) DNA single-strand breaks in kidneys of Syrian hamsters treated with steroidal estrogens: Hormone-induced free radical damage preceding renal malignancy. *Carcinogenesis*, **15**, 997–1000
- Han, X. & Liehr, J.G. (1995) Microsome-mediated 8-hydroxylation of guanine bases of DNA by steroid estrogens: Correlation of DNA damage by free radicals with metabolic activation to quinones. *Carcinogenesis*, **16**, 2571–2574
- Han, X., Liehr, J.G. & Bosland, M.C. (1995) Induction of a DNA adduct detectable by <sup>32</sup>P-postlabelling in the dorsolateral prostate of NBL/Cr rats treated with estradiol-17 $\beta$  and testosterone. *Carcinogenesis*, **16**, 951–954



- Handa, V.L., Landerman, R., Hanlon, J.T., Harris, T. & Cohen, H.J. (1996) Do older women use estrogen replacement? Data from the Duke Established Populations for Epidemiologic Studies of the Elderly (EPESE). *J. Am. geriatr. Soc.*, **44**, 1–6
- Harlow, B.L., Weiss, N.S., Roth, G.J., Chu, J. & Daling, J.R. (1988) Case-control study of borderline ovarian tumors: Reproductive history and exposure to exogenous female hormones. *Cancer Res.*, **48**, 5849–5852
- Harris, R.B., Laws, A., Reddy, V.M., King, A. & Haskell, W.L. (1990) Are women using postmenopausal estrogens? A community survey. *Am. J. public Health*, **80**, 1266–1268
- Harris, R.E., Namboodin, K.K. & Wynder, E.L. (1992a) Breast cancer risk: Effects of estrogen replacement therapy and body mass. *J. natl Cancer Inst.*, **84**, 1575–1582
- Harris, R., Whittemore, A.S., Itnyre, J. & the Collaborative Ovarian Cancer Group (1992b) Characteristics relating to ovarian cancer risk: Collaborative analysis of 12 US case-control studies. III. Epithelial tumors of low malignant potential in white women. *Am. J. Epidemiol.*, **136**, 1204–1211
- Hartge, P., Tucker, M.A., Shields, J.A., Augsburger, J., Hoover, R.N. & Fraumeni, J.F., Jr (1989) Case-control study of female hormones and eye melanoma. *Cancer Res.*, **49**, 4622–4625
- Haspels, A.A., Luisi, M. & Kicovic, P.M. (1981) Endocrinological and clinical investigations in post-menopausal women following administration of vaginal cream containing oestriol. *Maturitas*, **3**, 321–327
- Hassen, A.M., Lam, D., Chiba, M., Tan, E., Geng, W. & Pang, K.S. (1996) Uptake of sulfate conjugates by isolated rat hepatocytes. *Drug Metab. Disposition*, **24**, 792–798
- Hayashi, N., Hasegawa, K., Komine, A., Tanaka, Y., McLachlan, J.A., Barrett, J.C. & Tsutsui, T. (1996) Estrogen-induced cell transformation and DNA adduct formation in cultured Syrian hamster embryo cells. *Mol. Carcinogen.*, **16**, 149–156
- Hayes, C.L., Spink, D.C., Spink, B.C., Cao, J.Q., Walker, N.J. & Sutter, T.R. (1996) 17 $\beta$ -Estradiol hydroxylation catalyzed by human cytochrome P450 1B1. *Proc. natl Acad. Sci. USA*, **93**, 9776–9781
- Heimer, G.M. (1987) Estriol in the postmenopause. *Acta obstet. gynecol. scand.*, **139** (Suppl.), 1–23
- Hemminki, E., Kennedy, D.L., Baum, C. & McKinlay, S.M. (1988) Prescribing of noncontraceptive estrogens and progestins in the United States, 1974–86. *Am. J. public Health*, **78**, 1479–1481
- Hempling, R.E., Wong, C., Piver, M.S., Natarajan, N. & Mettlin, C.J. (1997) Hormone replacement therapy as a risk factor for epithelial ovarian cancer: Results of a case-control study. *Obstet. Gynecol.*, **89**, 1012–1216
- Henderson, B.E., Paganini-Hill, A. & Ross, R.K. (1991) Decreased mortality in users of estrogen replacement therapy. *Arch. intern. Med.*, **151**, 75–78
- Hermens, W.A., Deurloo, M.J., Romeyn, S.G., Verhoef, J.C. & Merkus, F.W. (1990) Nasal absorption enhancement of 17 beta-estradiol by dimethyl-beta-cyclodextrin in rabbits and rats. *Pharmacol. Res.*, **7**, 500–503
- Herrinton, L.J. & Weiss, N.S. (1993) Postmenopausal unopposed estrogens. Characteristics of use in relation to the risk of endometrial carcinoma. *Ann. Epidemiol.*, **3**, 308–318

- Hiatt, R.A., Bawol, R., Friedman, G.D. & Hoover, R. (1984) Exogenous estrogen and breast cancer after bilateral oophorectomy. *Cancer*, **54**, 139–144
- Highman, B., Greenman, D.L., Norvell, M.J., Farmer, J. & Shellenberger, T.E. (1980) Neoplastic and preneoplastic lesions induced in female C3H mice by diets containing diethylstilbestrol or 17 beta-estradiol. *J. environ. Pathol. Toxicol.*, **4**, 81–95
- Hildreth, N.G., Kelsey, J.L., LiVolsi, V.A., Fischer, D.B., Holford, T.R., Mostow, E.D., Schwartz, P.E. & White, C. (1981) An epidemiologic study of epithelial carcinoma of the ovary. *Am. J. Epidemiol.*, **114**, 398–405
- Hill, A. & Wolff, S. (1983) Sister chromatid exchanges and cell division delays induced by diethylstilbestrol, estradiol, and estriol in human lymphocytes. *Cancer Res.*, **43**, 4114–4118
- Hill, D.E., Slikker, W., Helton, E.D., Lipe, G.W., Newport, G.D., Sziszak, T.J. & Bailey, J.R. (1980) Transplacental pharmacokinetics and metabolism of diethylstilbestrol and 17 $\beta$ -estradiol in the pregnant rhesus monkey. *J. clin. Endocrinol. Metab.*, **50**, 811–818
- Hillbertz-Nilsson, K. & Forsberg, J.-G. (1985) Estrogen effects on sister chromatid exchanges in mouse uterine cervical and kidney cells. *J. natl Cancer Inst.*, **75**, 575–580
- Hislop, T.G., Coldman, A.J., Elwood, J.M., Brauer, G. & Kan, L. (1986) Childhood and recent eating patterns and risk of breast cancer. *Cancer Detect. Prevent.*, **9**, 47–58
- Holford, T.R., Roush, G.C. & McKay, L.A. (1991) Trends in female breast cancer in Connecticut and the United States. *J. clin. Epidemiol.*, **44**, 29–39
- Holly, E.A., Weiss, N.S. & Liff, J.M. (1983) Cutaneous melanoma in relation to exogenous hormones and reproductive factors. *J. natl Cancer Inst.*, **70**, 827–831
- Holly, E.A., Cress, R.D. & Ahn, D.K. (1994) Cutaneous melanoma in women: Ovulatory life, menopause, and use of exogenous estrogens. *Cancer Epidemiol. Biomarkers Prev.*, **3**, 661–668
- Holman, C.D.J., Armstrong, B.K. & Heenan, P.J. (1984) Cutaneous malignant melanoma in women: Exogenous sex hormones and reproductive factors. *Br. J. Cancer*, **50**, 673–680
- Hoogerland, D.L., Buchler, D.A., Crowley, J.J. & Carr, W.F. (1978) Estrogen use—risk of endometrial carcinoma. *Gynecol. Oncol.*, **6**, 451–458
- Hoover, R., Gray, L.A., Sr, Cole, P. & MacMahon, B. (1976) Menopausal estrogens and breast cancer. *New Engl. J. Med.*, **295**, 401–405
- Hoover, R., Glass, A., Finkle, W.D., Azevedo, D. & Milne, K. (1981) Conjugated estrogens and breast cancer risk in women. *J. natl Cancer Inst.*, **67**, 815–820
- Hulka, B.S., Fowler, W.C., Jr, Kaufman, D.G., Grimson, R.C., Greenberg, B.G., Hogue, C.J., Berger, G.S. & Pulliam, C.C. (1980) Estrogen and endometrial cancer: Cases and two control groups from North Carolina. *Am. J. Obstet. Gynecol.*, **137**, 92–101
- Hulka, B.S., Chambless, L.E., Deubner, D.C. & Wilkinson, W.E. (1982) Breast cancer and estrogen replacement therapy. *Am. J. Obstet. Gynecol.*, **143**, 638–644
- Hunt, K., Vessey, M., McPherson, K. & Coleman, M. (1987) Long-term surveillance of mortality and cancer incidence in women receiving hormone replacement therapy. *Br. J. Obstet. Gynaecol.*, **94**, 620–635
- Hunt, K., Vessey, M. & McPherson, K. (1990) Mortality in a cohort of long-term users of hormone replacement therapy: An updated analysis. *Br. J. Obstet. Gynaecol.*, **97**, 1080–1086

- Hyder, S.M., Murthy, L. & Stancel, G.M. (1998) Progesterin regulation of vascular endothelial growth factor in human breast cancer cells. *Cancer Res.*, **58**, 392–395
- IARC (1979) *IARC Monographs on the Evaluation of the Carcinogenic Risk of Chemicals to Humans*, Vol. 21, *Sex Hormones (II)*, Lyon, pp. 279–326, 327–341, 343–362, 491–515
- Inano, H., Yamanouchi, H., Suzuki, K., Onoda, M. & Wakabayashi, K. (1995) Estradiol-17 $\beta$  as an initiation modifier for radiation-induced mammary tumorigenesis of rats ovariectomized before puberty. *Carcinogenesis*, **16**, 1871–1877
- Ingerowski, G.H., Scheutwinkel-Reich, M. & Stan, H.-J. (1981) Mutagenicity studies on veterinary anabolic drugs with the *Salmonella*/microsome test. *Mutat. Res.*, **91**, 93–98
- Jacobs, E.J., White, E. & Weiss, N.S. (1994) Exogenous hormones, reproductive history, and colon cancer (Seattle, Washington, USA). *Cancer Causes Control*, **5**, 359–366
- Jacobson, J.S., Neugut, A.I., Garbowski, G.D., Ahsan, H., Wayne, J.D., Treat, M.R. & Forde, K.A. (1995) Reproductive risk factors for colorectal adenomatous polyps (New York City, NY, United States). *Cancer Causes Control*, **6**, 513–518
- Jasonni, V.M., Bulletti, C., Naldi, S., Ciotti, P., Di Cosmo, D., Lazaretto, R. & Flamigni, C. (1988) Biological and endocrine aspects of transdermal 17 $\beta$ -oestradiol administration in postmenopausal women. *Maturitas*, **10**, 263–270
- Jelovsek, F.R., Hammond, C.B., Woodard, B.H., Draffin, R., Lev, K.L., Craesman, W.T. & Parker, R.T. (1980) Risk of exogenous estrogen therapy and endometrial cancer. *Am. J. Obstet. Gynecol.*, **137**, 85–91
- Jeng, M.-H. & Jordan V.C. (1991) Growth stimulation and differential regulation of transforming growth factor- $\beta$ 1 (TGF  $\beta$ 1), TGF  $\beta$ 2, and TGF  $\beta$ 3 messenger RNA levels by norethindrone in MCF-7 human breast cancer cells. *Mol. Endocrinol.*, **8**, 1120–1128
- Jeng, M.-H., Parker, C.J. & Jordan, V.C. (1992) Estrogenic potential of progestins in oral contraceptives to stimulate human breast cancer cell proliferation. *Cancer Res.*, **52**, 6539–6546
- Jewelewicz, R. (1997) New developments in topical estrogen therapy. *Fertil. Steril.*, **67**, 1–12
- Jick, S.S., Walker, A.M. & Jick, H. (1993) Estrogens, progesterone, and endometrial cancer. *Epidemiology*, **4**, 20–24
- Johannes, C.B., Crawford, S.L., Posner, J.G. & McKinlay, S.M. (1994) Longitudinal patterns and correlates of hormone replacement therapy use in middle-aged women. *Am. J. Epidemiol.*, **140**, 439–452
- Johnston, A. (1996) Estrogens—Pharmacokinetics and pharmacodynamics with special reference to vaginal administration and the new estradiol formulation—Estring®. *Acta obstet. gynecol. scand.*, **75**, 16–25
- Jolleys, J.V. & Olesen, F. (1996) A comparative study of prescribing of hormone replacement therapy in USA and Europe. *Maturitas*, **23**, 47–53
- Kalkhoven, E., Kwakkenbos-Isbrücker, L., de Laat, S.W., van der Saag, P.T. & Van der Burg, B. (1994) Synthetic progestins induce proliferation of breast tumor cell lines via the progesterone or estrogen receptor. *Mol. cell. Endocrinol.*, **102**, 45–52
- Kaltenbach, C.C., Dunn, T.G., Koritnik, D.R., Tucker, W.F., Batson, D.B., Staigmiller, R.B. & Niswender, G.D. (1976) Isolation and identification of metabolites of <sup>14</sup>C-labeled estradiol in cattle. *J. Toxicol. environ. Health*, **1**, 607–616

- Kampman, E., Potter, J.D., Slattery, M.L., Caan, B.J. & Edward, S. (1997) Hormone replacement therapy, reproductive history, and colon cancer: A multicenter, case-control study in the United States. *Cancer Causes Control*, **8**, 146–158
- Katzenellenbogen, B.S. (1984) Biology and receptor interactions of estriol and estriol derivatives *in vitro* and *in vivo*. *J. Steroid Biochem.*, **20**, 1033–1037
- Katzenellenbogen, B.S., Bhardwaj, B., Fang, H., Ince, B.A., Pakdel, F., Reese, J.C., Schodin, D. & Wrenn, C.K. (1993) Hormone binding and transcription activation by estrogen receptors: Analyses using mammalian and yeast systems. *J. Steroid Biochem. mol. Biol.*, **47**, 39–48
- Kaufman, D.W., Miller, D.R., Rosenberg, L., Helmrich, S.P., Stolley, P., Schottenfeld, D. & Shapiro, S. (1984) Noncontraceptive estrogen use and the risk of breast cancer. *J. Am. med. Assoc.*, **252**, 63–67
- Kaufman, D.W., Kelly, J.P., Welch, W.R., Rosenberg, L., Stolley, P.D., Warshauer, M.E., Lewis, J., Woodruff, J. & Shapiro, S. (1989) Noncontraceptive estrogen use and epithelial ovarian cancer. *Am. J. Epidemiol.*, **130**, 1142–1151
- Kaufman, D.W., Palmer, J.R., de Mouzon, J., Rosenberg, L., Stolley, P.D., Warshauer, M.E., Zauber, A.G. & Shapiro, S. (1991) Estrogen replacement therapy and the risk of breast cancer: Results from the case-control surveillance study. *Am. J. Epidemiol.*, **134**, 1375–1385
- Kay, C.R. & Hannaford, P.C. (1988) Breast cancer and the pill—A further report from the Royal College of General Practitioners' Oral Contraception Study. *Br. J. Cancer*, **58**, 675–680
- Keating, N.L., Cleary, P.D., Rossi, A.S. & Ayanian, J.Z. (1997) Use of hormone replacement therapy in a national sample of postmenopausal women (Abstract). *J. gen. intern. Med.*, **12** (Suppl.), 127
- Kelsey, J.L., Livolsi, V.A., Holford, T.R., Fisher, D.B., Mostow, E.D., Schwartz, P.E., O'Connor, T. & White, C. (1982) A case-control study of cancer of the endometrium. *Am. J. Epidemiol.*, **116**, 333–342
- Kelsey, J.L., Gammon, M.D. & John, E.M. (1993) Reproductive factors and breast cancer. *Epidemiol. Rev.*, **15**, 36–47
- Kennedy, A.R. & Wiechselbaum, R.R. (1981) Effects of 17 $\beta$ -estradiol on radiation transformation *in vitro*; inhibition of effects by protease inhibitors. *Carcinogenesis*, **2**, 67–69
- Kennedy, D.L., Baum, C. & Forbes, M.B. (1985) Noncontraceptive estrogens and progestins: Use patterns over time. *Obstet. Gynecol.*, **65**, 441–446
- Kerlan, V., Dreano, Y., Bercovici, J.P., Beaune, P.H., Floch, H.H. & Berthou, F. (1992) Nature of cytochrome P450 involved in 2-/4-hydroxylations of estradiol in human liver microsomes. *Biochem. Pharmacol.*, **44**, 1745–1756
- Kim, Y.B., Berek, J.S., Martinez-Maza, O. & Satyaswaroop, P.G. (1996) Vascular endothelial growth factor expression is not regulated by estradiol or medroxyprogesterone acetate in endometrial carcinoma. *Gynecol. Oncol.*, **61**, 97–100
- King, R.J.B. (1991) Biology of female sex hormone action in relation to contraceptive agents and neoplasia. *Contraception*, **43**, 527–542
- Kitawaki, J., Fukuoka, M., Yamamoto, T., Honjo, H. & Okada, H. (1992) Contribution of aromatase to the deoxyribonucleic acid synthesis of MCF-7 human breast cancer cells and its suppression by aromatase inhibitors. *J. Steroid Biochem. mol. Biol.*, **42**, 267–277

- Knabbe, C., Lippman, M.E., Wakefield, L.M., Flanders, K.C., Kasid, A., Derynck, R. & Dickson, R.B. (1987) Evidence that transforming growth factor- $\beta$  is a hormonally regulated negative growth factor in human breast cancer cells. *Cell*, **48**, 417–428
- Koibuchi, Y., Iino, Y., Uchida, T., Nagasawa, M. & Morishita, Y. (1997) Effects of estrogen and tamoxifen on the MAP kinase cascade in experimental rat breast cancer. *Int. J. Oncol.*, **11**, 583–589
- Koike, S., Sakai, M. & Muramatsu, M. (1987) Molecular cloning and characterization of rat estrogen receptor cDNA. *Nucleic Acids Res.*, **15**, 2499–2513
- Kolonel, L.N., Hankin, J.H., Wilkens, L.R., Fukunaga, F.H. & Hinds, M.W. (1990) An epidemiologic study of thyroid cancer in Hawaii. *Cancer Cases Control*, **1**, 223–234
- Koper, N.P., Kiemeny, L.A.L.M., Massuger, L.F.A.G., Thomas, C.M.G., Schijf, C.P.T. & Verbeek, A.L.M. (1996) Ovarian cancer incidence (1989–1991) and mortality (1954–1993) in The Netherlands. *Obstet. Gynecol.*, **88**, 387–393
- Kopera, H. & van Keep, P.A. (1991) Development and present state of hormone replacement therapy. *Int. J. clin. Pharmacol.*, **29**, 412–417
- Køster, A. (1990) Hormone replacement therapy: Use patterns in 51-year-old Danish women. *Maturitas*, **12**, 345–356
- Koumantaki, Y., Tzonou, A., Koumantakis, E., Kaklamani, E., Aravantinos, D. & Trichopoulos, D. (1989) A case–control study of cancer of endometrium in Athens. *Int. J. Cancer*, **43**, 795–799
- Kravdal, Ø., Glattre, E. & Haldorsen, T. (1991) Positive correlation between parity and incidence of thyroid cancer: New evidence based on complete Norwegian birth cohorts. *Int. J. Cancer*, **49**, 831–836
- Krust, A., Green, S., Argos, P., Kumar, V., Walter, P., Bornert, J.-M. & Chambon, P. (1986) The chicken oestrogen receptor sequence: Homology with *v-erbA* and the human oestrogen and glucocorticoid receptors. *EMBO J.*, **5**, 891–897
- Kuh, D.L., Wadsworth, M. & Hardy, R. (1997) Women's health in midlife: The influence of the menopause, social factors and health in earlier life. *Br. J. Obstet. Gynaecol.*, **104**, 923–933
- Kuhl, H. (1990) Pharmacokinetics of oestrogens and progestogens. *Maturitas*, **12**, 171–197
- Kuiper, G.G.J.M., Enmark, E., Peltö-Huikko, M., Nilsson, S. & Gustafsson, J.-Å. (1996) Cloning of a novel estrogen receptor expressed in rat prostate and ovary. *Proc. natl Acad. Sci. USA*, **93**, 5925–5930
- Lafferty, F.W. & Helmuth, D.O. (1985) Post-menopausal estrogen replacement: The prevention of osteoporosis and systemic effects. *Maturitas*, **7**, 147–159
- Lancaster, T., Surman, G., Lawrence, M., Mant, D., Vessey, M., Thorogood, M., Yudkin, P. & Daly, E. (1995) Hormone replacement therapy: Characteristics of users and non-users in a British general practice cohort identified through computerised prescribing records. *J. Epidemiol. Community Health*, **49**, 389–394
- Lang, R. & Redmann, U. (1979) Non-mutagenicity of some sex hormones in the Ames *Salmonella*/microsome mutagenicity test. *Mutat. Res.*, **67**, 361–365

- Lang, R. & Reimann, R. (1993) Studies for a genotoxic potential of some endogenous and exogenous steroids. I. Communication: Examination for the induction of gene mutations using the Ames *Salmonella*/microsome test and the HGPRT test in V79 cells. *Environ. mol. Mutag.*, **21**, 272–304
- La Vecchia, C., Franceschi, S., Gallus, G., Decarli, A., Colombo, E., Mangioni, C. & Tognoni, G. (1982a) Oestrogens and obesity as risk factors for endometrial cancer in Italy. *Int. J. Epidemiol.*, **11**, 120–126
- La Vecchia, C., Liberati, A. & Franceschi, S. (1982b) Noncontraceptive estrogen use and the occurrence of ovarian cancer (Letter to the Editor). *J. natl Cancer Inst.*, **69**, 1207
- La Vecchia, C., Franceschi, S., Decarli, A., Gallus, G. & Tognoni, G. (1984) Risk factors for endometrial cancer at different ages. *J. natl Cancer Inst.*, **73**, 667–671
- La Vecchia, C., Decarli, A., Parazzini, F., Gentile, A., Liberati, C. & Franceschi, S. (1986) Non-contraceptive oestrogens and the risk of breast cancer in women. *Int. J. Cancer*, **38**, 853–858
- La Vecchia, C., Negri, E., Franceschi, S. & Parazzini, F. (1992a) Non-contraceptive oestrogens and breast cancer. *Int. J. Cancer*, **50**, 161–162
- La Vecchia, C., Lucchini, F., Negri, E., Boyle, P., Maisonneuve, P. & Levi, F. (1992b) Trends of cancer mortality in Europe, 1955–1989: III. Breast and genital sites. *Eur. J. Cancer*, **28A**, 927–998
- La Vecchia, C., D'Avanzo, B., Franceschi, S., Negri, E., Parazzini, F., Decarli, A. (1994) Menstrual and reproductive factors and gastric-cancer risk in women. *Int. J. Cancer*, **59**, 761–764
- La Vecchia, C., Negri, E., Franceschi, S., Favero, A., Nanni, O., Filiberti, R., Conti, E., Montella, M., Veronesi, A., Ferraroni, M. & Decarli, A. (1995) Hormone replacement treatment and breast cancer risk: A cooperative Italian study. *Br. J. Cancer*, **72**, 244–248
- La Vecchia, C., Negri, E., Levi, F., Decarli, A. & Boyle, P. (1998) Cancer mortality in Europe: Effects of age, cohort of birth and period of death. *Eur. J. Cancer*, **34**, 118–141
- Lee, N.C., Rosero-Bixby, L., Oberle, M.W., Grimaldo, C., Whatley, A.S. & Rovira, E.Z. (1987) A case-control study of breast cancer and hormonal contraception in Costa Rica. *J. natl Cancer Inst.*, **79**, 1247–1254
- Lemon, H.M. (1987) Antimammary carcinogenic activity of 17-alpha-ethinyl estriol. *Cancer*, **60**, 2873–2881
- Lemon, H.M., Kumar, P.F., Peterson, C., Rodriguez-Sierra, J.F. & Abbo, K.M. (1989) Inhibition of radiogenic mammary carcinoma in rats by estriol or tamoxifen. *Cancer*, **63**, 1685–1692
- Levi, F., La Vecchia, C., Gulie, C., Franceschi, S. & Negri, E. (1993a) Oestrogen replacement treatment and the risk of endometrial cancer: An assessment of the role of covariates. *Eur. J. Cancer*, **29A**, 1445–1449
- Levi, F., Franceschi, S., Gulie, C., Negri, E. & La Vecchia, C. (1993b) Female thyroid cancer: The role of reproductive and hormonal factors in Switzerland. *Oncology*, **50**, 309–315
- Levi, F., Lucchini, F., Pasche, C. & La Vecchia, C. (1996) Oral contraceptives, menopausal hormone replacement treatment and breast cancer risk. *Eur. J. Cancer Prev.*, **5**, 259–266
- Lew, R.A., Sober, A.J., Cook, N., Marvell, R. & Fitzpatrick, T.B. (1983) Sun exposure habits in patients with cutaneous melanoma: A case-control study. *J. Dermatol. surg. Oncol.*, **9**, 981–986

- Li, J.J. & Li, S.A. (1987) Estrogen carcinogenesis in Syrian hamster tissues: Role of metabolism. *Fed. Proc.*, **46**, 1858–1863
- Li, J.J., Li, S.A., Klicka, J.K., Parsons, J.A. & Lam, L.K. (1983) Relative carcinogenic activity of various synthetic and natural estrogens in the Syrian hamster kidney. *Cancer Res.*, **43**, 5200–5204
- Li, J.J., Gonzalez, A., Banerjee, S., Banerjee, S.K. & Li, S.A. (1993) Estrogen carcinogenesis in the hamster kidney: Role of cytotoxicity and cell proliferation. *Environ. Health Perspectives*, **101** (Suppl. 5), 259–264
- Li, S.A., Xue, Y., Xie, Q., Li, C.I. & Li, J.J. (1994) Serum and tissue levels of estradiol during estrogen-induced renal tumorigenesis in the Syrian hamster. *J. Steroid Biochem. mol. Biol.*, **48**, 283–286
- Li, J.J., Li, S.A., Oberley, T.D. & Parsons, J.A. (1995) Carcinogenic activities of various steroidal and nonsteroidal estrogens in the hamster kidney: Relation to hormonal activity and cell proliferation. *Cancer Res.*, **55**, 4347–4351
- Liehr, J.G. & Ricco, M.J. (1996) 4-Hydroxylation of estrogens as marker of human mammary tumors. *Proc. natl Acad. Sci. USA*, **93**, 3294–3296
- Liehr, J.G. & Roy, D. (1990) Free radical generation by redox cycling of estrogen. *Free Rad. Biol. Med.*, **8**, 415–423
- Liehr, J.G., Fang, W.-F., Sirbasku, D.A. & Ari-Ulubelen, A. (1986a) Carcinogenicity of catechol estrogens in Syrian hamsters. *J. Steroid Biochem.*, **24**, 353–356
- Liehr, J.G., Ulubelen, A.A. & Strobel, H.W. (1986b) Cytochrome P450-mediated redox cycling of estrogens. *J. biol. Chem.*, **261**, 16865–16870
- Liehr, J.G., Avitts, T.A., Randerath, E. & Randerath, K. (1986c) Estrogen-induced endogenous DNA adduction: Possible mechanism of hormonal cancer. *Proc. natl Acad. Sci. USA*, **83**, 5302–5305
- Liehr, J.G., Purdy, R.H., Baran, J.S., Nutting, E.F., Colton, F., Randerath, E. & Randerath, K. (1987a) Correlation of aromatic hydroxylation of 11 $\beta$ -substituted estrogens with morphological transformation *in vitro* but not with *in vivo* tumour induction by these hormones. *Cancer Res.*, **47**, 2583–2588
- Liehr, J.G., Hall, E.R., Avitts, T.A., Randerath, E. & Randerath, K. (1987b) Localisation of estrogen-induced DNA adducts and cytochrome P-450 activity at the site of renal carcinogenesis in the hamster kidney. *Cancer Res.*, **47**, 2156–2159
- Liehr, J.G., Han, X. & Bhat, H.K. (1993) <sup>32</sup>P-Postlabelling in studies of hormonal carcinogenesis. In: Phillips, D.H., Castegnaro, M. & Bartsch, H., eds, *Postlabelling Methods for Detection of DNA Adducts* (IARC Scientific Publications No. 124), Lyon, IARC, pp. 149–155
- Liehr, J.G., Ricci, M.J., Jefcoate, C.R., Hannigan, E.V., Hokanson, J.A. & Zhu, B.T. (1995) 4-Hydroxylation of estradiol by human uterine myometrium and myoma microsomes: Implication for the mechanism of uterine tumorigenesis. *Proc. natl Acad. Sci. USA*, **92**, 9220–9224
- Lindblad, P., Mellempgaard, A., Schlehofer, B., Adami, H.-O., McCredie, M., McLaughlin, J.K. & Mandel, J.S. (1995) International renal-cell cancer study. V. Reproductive factors, gynecologic operations and exogenous hormones. *Int. J. Cancer*, **61**, 192–198

- Lindgren, R., Berg, G., Hammarm, M. & Zuccon, E. (1993) Hormonal replacement therapy and sexuality in a population of Swedish postmenopausal women. *Acta obstet. gynecol. scand.*, **72**, 292–297
- Lippman, M.E. & Dickson, R.B. (1989) Mechanisms of normal and malignant breast epithelial growth regulation. *J. Steroid Biochem.*, **34**, 107–121
- Lipworth, L., Katsouyanni, K., Stuver, S., Samoli, E., Hankinson, S. & Trichopoulos, D. (1995) Oral contraceptives, menopausal oestrogens and the risk of breast cancer: A case-control study in Greece. *Int. J. Cancer*, **62**, 548–551
- Longcope, C., Flood, C. & Tast, J. (1994) The metabolism of estrone sulfate in the female rhesus monkey. *Steroids*, **59**, 270–273
- Lu, L.J.W., Liehr, J.G., Sirbasku, D.A., Randerath, E. & Randerath, K. (1988) Hypomethylation of DNA in estrogen-induced and -dependent hamster kidney tumours. *Carcinogenesis*, **9**, 925–929
- Lubahn, D.B., McCarty, K.S., Jr & McCarty, K.S., Sr (1985) Electrophoretic characterization of purified bovine, porcine, murine, rat, and human uterine estrogen receptors. *J. biol. Chem.*, **260**, 2515–2526
- Luo, S., Stojanovic, M., Labrie, C. & Labrie, F. (1997) Inhibitory effect of the novel anti-estrogen EM-800 and medroxyprogesterone acetate on estrone-stimulated growth of dimethylbenz[a]-anthracene-induced mammary carcinoma in rats. *Int. J. Cancer*, **73**, 580–586
- Mack, T.M., Pike, M.C., Henderson, B.E., Pfeffer, R.I., Gerkins, V.R., Arthur, M. & Brown, S.E. (1976) Estrogens and endometrial cancer in a retirement community. *New Engl. J. Med.*, **294**, 1262–1267
- MacLennan, A.H., MacLennan, A. & Wilson, D. (1993) The prevalence of oestrogen replacement therapy in South Australia. *Maturitas*, **16**, 175–183
- Maddison, J. (1973) Hormone replacement therapy for menopausal symptoms (Letter to the Editor). *Lancet*, **i**, 1507
- Magnusson, C., Holmberg, L., Norden, T., Lindgren, A. & Persson, I. (1996) Prognostic characteristics in breast cancers after hormone replacement therapy. *Breast Cancer Res. Treat.*, **38**, 325–334
- Markiewicz, L. & Gurbide, E. (1994) Estrogenic and progestagenic activities coexisting in steroidal drugs: Quantitative evaluation by *in vitro* bioassays with human cells. *J. Steroid Biochem. mol. Biol.*, **48**, 89–94
- Markiewicz, L., Hochberg, R.B. & Gurbide, E. (1992) Intrinsic estrogenicity of some progestagenic drugs. *J. Steroid Biochem. mol. Biol.*, **41**, 53–58
- Martin, J.H.J., McKibben, B.M., Lynch, M. & van den Berg, H.W. (1991) Modulation by oestrogen and progestins/antiprogestins of alpha interferon receptor expression in human breast cancer cells. *Eur. J. Cancer*, **27**, 143–146
- Marubini, E., Decarli, A., Costa, A., Marroleni, C., Andreoli, C., Barbieri, A., Capitelli, E., Carlucci, M., Cavallo, F., Monferroni, N., Pastorino, U. & Salvini, S. (1988) The relationship of dietary intake and serum levels of retinol and beta-carotene with breast cancer: Results of a case-control study. *Cancer*, **61**, 173–180



- McDonald, T.W., Annegers, J.F., O'Fallon, W.M., Dockerty, M.B., Malkasian, G.D., Jr & Kurland, L.T. (1977) Exogenous estrogen and endometrial carcinoma: Case-control and incidence study. *Am. J. Obstet. Gynecol.*, **127**, 572-580
- McDonnell, D.P., Clemm, D.L., Hermann, T., Goldman, M.E. & Pike, J.W. (1995) Analysis of estrogen receptor function *in vitro* reveals three distinct classes of antiestrogens. *Mol. Endocrinol.*, **9**, 659-669
- McLachlan, J.A. & Newbold, R.R. (1996) Cellular and molecular mechanisms of cancers of the uterus in animals. In: Huff, J., Boyd, J. & Barrett, J.C., eds, *Cellular and Molecular Mechanisms of Hormonal Carcinogenesis: Environmental Influences*, New York, Wiley-Liss, pp. 175-182
- McPherson, K., Vessey, M.P., Neil, A., Doll, R., Jones, L. & Roberts, M. (1987) Early oral contraceptive use and breast cancer: Results of another case-control study. *Br. J. Cancer*, **56**, 653-660
- McTiernan, A.M., Weiss, N.S. & Daling, J.R. (1984) Incidence of thyroid cancer in women in relation to reproductive and hormonal factors. *Am. J. Epidemiol.*, **120**, 423-435
- Miller, A.B., Baines, C.J., To, T. & Wall, C. (1992) Canadian National Breast Screening Study. I. Breast cancer detection and death rates among women aged 40-49 years. *Can. med. Assoc. J.*, **147**, 1459-1476
- Mills, P.K., Beeson, W.L., Phillips, R.L. & Fraser, G.E. (1989) Prospective study of exogenous hormone use and breast cancer in Seventh-day Adventists. *Cancer*, **64**, 591-597
- Morabia, A., Szklo, M., Stewart, W., Schuman, L. & Thomas, D.B. (1993) Consistent lack of association between breast cancer and oral contraceptives using either hospital or neighbourhood controls. *Prev. Med.*, **22**, 178-186
- Murase, T., Niwa, K., Morishita, S., Itoh, N., Mori, H., Tanaka, T. & Tamaya, T. (1995) Rare occurrence of *p53* and *ras* gene mutations in preneoplastic and neoplastic mouse endometrial lesions induced by *N*-methyl-*N*-nitrosourea and 17 $\beta$ -estradiol. *Cancer Lett.*, **92**, 223-227
- Musgrove, E.A. & Sutherland, R.L. (1997) Steroidal control of cell proliferation in the breast and breast cancer. In: Wren, B.G., ed., *Progress in the Management of the Menopause*, New York, Parthenon Publishing Group, pp. 194-202
- Nabulsi, A.A., Folsom, A.R., White, A., Patsch, W., Heiss, G., Wu, K.K. & Szklo, M. (1993) Association of hormone-replacement therapy with various cardiovascular risk factors in postmenopausal women. The Atherosclerosis Risk in Communities study investigators. *New Engl. J. Med.*, **328**, 1069-1075
- Nagata, C., Matsushita, Y. & Shimizu, H. (1996) Prevalence of hormone replacement therapy and user's characteristics: A community survey in Japan. *Maturitas*, **25**, 201-207
- National Corporation of Pharmacies (1997) *Sales Statistics of Defined Daily Doses/1000 Women, 1947-1997*, Stockholm, Apoteket AB
- Nawata, H., Yamamoto, R.S. & Poirer, L.A. (1981) Elevated levels of ornithine decarboxylase and polyamines in the kidneys of estradiol-treated male hamsters. *Carcinogenesis*, **11**, 1207-1211

- Negri, E., La Vecchia, C., Parazzini, F., Savoldelli, R., Gentile, A., D'Avanzo, B., Gramenzi, A. & Franceschi, S. (1989) Reproductive and menstrual factors and risk of colorectal cancer. *Cancer Res.*, **49**, 7158–7161
- Newcomb, P.A. & Storer, B.E. (1995) Postmenopausal hormone use and risk of large-bowel cancer. *J. natl Cancer Inst.*, **87**, 1067–1071
- Newcomb, P.A., Longnecker, M.P., Storer, B.E., Mittendorf, R., Baron, J., Clapp, R.W., Trentham-Dietz, A. & Willett, W.C. (1995) Long-term hormone replacement therapy and risk of breast cancer in postmenopausal women. *Am. J. Epidemiol.*, **142**, 788–795
- Ngelangel, C.A., Lacaya, L.B., Cordero, C. & Laudico, A.V. (1994) Risk factors for breast cancer among Filipino women. *Phil. J. intern. Med.*, **32**, 231–236
- Ni, N. & Yager, J.D. (1994a) Comitogenic effects of estrogens on DNA synthesis induced by various growth factors in cultured female rat hepatocytes. *Hepatology*, **19**, 183–192
- Ni, N. & Yager, J.D. (1994b) The comitogenic effects of various estrogens for TGF- $\alpha$ -induced DNA synthesis in cultured female rat hepatocytes. *Cancer Lett.*, **84**, 133–140
- Niwa, K., Tanaka, T., Mori, H., Yokoyama, Y., Furui, T., Mori, H. & Tamaya, T. (1991) Rapid induction of endometrial carcinoma in ICR mice treated with N-methyl-N-nitrosourea and 17 $\beta$ -estradiol. *Jpn. J. Cancer Res.*, **82**, 1391–1396
- Niwa, K., Murase, T., Furui, T., Morishita, S., Mori, H., Tanaka, T., Mori, H. & Tamaya, T. (1993) Enhancing effects of estrogens on endometrial carcinogenesis initiated by N-methyl-N-nitrosourea in ICR mice. *Jpn. J. Cancer Res.*, **84**, 951–955
- Niwa, K., Morishita, S., Murase, T., Mudigdo, A., Tanaka, T., Mori, H. & Tamaya, T. (1996) Chronological observation of mouse endometrial carcinogenesis induced by N-methyl-N-nitrosourea and 17beta-estradiol. *Cancer Lett.*, **104**, 115–119
- Nomura, A.M., Kolonel, L.N., Hirohata, T. & Lee, J. (1986) The association of replacement estrogens with breast cancer. *Int. J. Cancer*, **37**, 49–53
- Nutter, L.M., Wu, Y.Y., Ngo, E.O., Sierra, E.E., Gutierrez, P.L. & Abul-Hajj, Y.J. (1994) An o-quinone form of estrogen produces free radicals in human breast cancer cells: Correlation with DNA damage. *Chem. Res. Toxicol.*, **7**, 23–28
- Ochs, H., Dusterberg, B., Gunzel, P. & Schulte-Hermann, R. (1986) Effect of tumor promoting contraceptive steroids on growth and drug metabolizing enzymes in rat liver. *Cancer Res.*, **46**, 1224–1232
- O'Connell, M.B. (1995) Pharmacokinetic and pharmacologic variation between different estrogen products. *J. clin. Pharmacol.*, **35**, 18S–24S
- Oddens, B.J. & Boulet, M.J. (1997) Hormone replacement therapy among Danish women aged 45–65 years: Prevalence, determinants and compliance. *Obstet. Gynecol.*, **90**, 269–277
- Østerlind, A., Tucker, M.A., Stone, B.J. & Jensen, O.M. (1988) The Danish case-control study of cutaneous malignant melanoma. III. Hormonal and reproductive factors in women. *Int. J. Cancer*, **42**, 821–824
- Paganini-Hill, A., Ross, R.K. & Henderson, B.E. (1989) Endometrial cancer and patterns of use of oestrogen replacement therapy: A cohort study. *Br. J. Cancer*, **59**, 445–447

- Palmer, J.R., Rosenberg, L., Clarke, E.A., Miller, D.R. & Shapiro, S. (1991) Breast cancer risk after estrogen replacement therapy: Results from the Toronto breast cancer study. *Am. J. Epidemiol.*, **134**, 1386–1395
- Pan, C.C., Woolever, C.A. & Bhavnani, B.R. (1985) Transport of equine estrogens: Binding of conjugated and unconjugated equine estrogens with human serum proteins. *J. clin. Endocrinol. Metab.*, **61**, 499–507
- Parazzini, F., La Vecchia, C., Negri, E. & Villa, A. (1994) Estrogen replacement therapy and ovarian cancer risk. *Int. J. Cancer*, **57**, 135–136
- Parazzini, F., La Vecchia, C., Negri, E., Franceschi, S., Moroni, S., Chatenoud, L. & Bolis, G. (1997) Case-control study of oestrogen replacement therapy and risk of cervical cancer. *Br. med. J.*, **315**, 85–88
- Parker, M.G. (1995) Structure and function of estrogen receptors. *Vitam. Horm.*, **51**, 267–287
- Pater, A., Bayatpour, M. & Pater, M.M. (1990) Oncogenic transformation by human papilloma virus type 16 deoxyribonucleic acid in the presence of progesterone or progestins from oral contraceptives. *Am. J. Obstet. Gynecol.*, **162**, 1099–1103
- Paul, C., Skegg, D.C.G. & Spears, G.F.S. (1990) Oral contraceptives and risk of breast cancer. *Int. J. Cancer*, **46**, 366–373
- Pedersen, S.H. & Jeune, B. (1988) Prevalence of hormone replacement therapy in a sample of middle-aged women. *Maturitas*, **9**, 339–345
- Peek, M.J., Markham, R. & Fraser, I.S. (1995) The effects of natural and synthetic sex steroids on human decidual endothelial cell proliferation. *Hum. Reprod.*, **10**, 2238–2243
- Persky, V., Davis, F., Barrett, R., Ruby, E., Sailer, C. & Levy, P. (1990) Recent time trends in uterine cancer. *Am. J. public Health*, **80**, 935–939
- Persson, I., Adami, H.-O., Lindberg, B.S., Johansson, E.D.B. & Manell, P. (1983) Practice and patterns of estrogen treatment in climacteric women in a Swedish population. *Acta obstet. gynecol. scand.*, **62**, 289–296
- Persson, I., Adami, H.-O., Bergkvist, L., Lindgren, A., Pettersson, B., Hoover, R. & Schairer, C. (1989) Risk of endometrial cancer after treatment with oestrogens alone or in conjunction with progestogens: Results of a prospective study. *Br. med. J.*, **298**, 147–151
- Persson, I., Bergström, R., Sparén, P., Thörn, M. & Adami, H.-O. (1993) Trends in breast cancer incidence in Sweden 1958–1988 by time period and birth cohort. *Br. J. Cancer*, **68**, 1247–1253
- Persson, I., Yuen, J., Bergkvist, L. & Schairer, C. (1996) Cancer incidence and mortality in women receiving estrogen and estrogen-progestin replacement therapy—Long-term follow-up of a Swedish cohort. *Int. J. Cancer*, **67**, 327–332
- Persson, I., Bergkvist, L., Lindgren, C. & Yuen, J. (1997a) Hormone replacement therapy and major risk factors for reproductive cancer, osteoporosis and cardiovascular diseases: Evidence of confounding by exposure characteristics. *J. clin. Epidemiol.*, **50**, 611–618
- Persson, I., Thurffjell, E., Bergström, R. & Holmberg, L. (1997b) Hormone replacement therapy and the risk of breast cancer. Nested case-control study in a cohort of Swedish women attending mammography screening. *Int. J. Cancer*, **72**, 758–761

- Persson, I., Bergström, R., Barlow, L. & Adami, H.-O. (1998) Recent trends in breast cancer incidence in Sweden. *Br. J. Cancer*, **77**, 167–169
- Peters, R.K., Pike, M.C., Chang, W.W.L. & Mack, T.M. (1990) Reproductive factors and colon cancers. *Br. J. Cancer*, **61**, 741–748
- Petitti, D.B., Perlman, J.A. & Sidney, S. (1987) Noncontraceptive estrogens and mortality: Long-term follow-up of women in the Walnut Creek Study. *Obstet. Gynecol.*, **70**, 289–293
- Pike, M.C., Peters, R.K., Cozen, W., Probst-Hensch, N.M., Felix, J.C., Wan, P.C. & Mack, T.M. (1997) Estrogen–progestin replacement therapy and endometrial cancer. *J. natl Cancer Inst.*, **89**, 1110–1116
- Polychronopoulou, A., Tzonou, A., Hsieh, C., Kaprinis, G., Rebelakos, A., Toupadaki, N. & Trichopoulos, D. (1993) Reproductive variables, tobacco, ethanol, coffee and somatometry as risk factors for ovarian cancer. *Int. J. Cancer*, **55**, 402–407
- Porter, M., Penney, G.C., Russell, D., Russell, E. & Templeton, A. (1996) A population based survey of women’s experience of the menopause. *Br. J. Obstet. Gynaecol.*, **103**, 1025–1028
- Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial (1996) Effects of hormone replacement therapy on endometrial histology in postmenopausal women. *J. Am. med. Assoc.*, **275**, 370–375
- Potter, J.D. & McMichael, A.J. (1983) Large bowel cancer in women in relation to reproductive and hormonal factors: A case–control study. *J. natl Cancer Inst.*, **71**, 703–709
- Potter, J.D., Bostick, R.M., Grandits, G.A., Fosdick, L., Elmer, P., Wood, J., Grambsch, P. & Louis, T.A. (1996) Hormone replacement therapy is associated with lower risk of adenomatous polyps of the large bowel: The Minnesota Cancer Prevention Research Unit Case–Control Study. *Cancer Epidemiol. Biomarkers Prev.*, **5**, 779–784
- Price, T.M., Blauer, K.L., Hansen, M., Stanczyk, F., Lobo, R. & Bates, W.G. (1997) Single-dose pharmacokinetics of sublingual versus oral administration of micronized 17 $\beta$ -estradiol. *Obstet. Gynecol.*, **89**, 340–345
- Purdie, D., Green, A., Bain, C., Siskind, V., Ward, B., Hacker, N., Quinn, M., Wright, G., Russell, P. & Susil, B. for the Survey of Women’s Health Group (1995) Reproductive and other factors and risk of epithelial ovarian cancer: An Australian case–control study. *Int. J. Cancer*, **62**, 678–684
- Ravnihar, B., Primic Zakeli, M., Kosmeli, K. & Stare, J. (1988) A case–control study of breast cancer in relation to oral contraceptive use in Slovenia. *Neoplasma*, **35**, 109–121
- Reynolds, J.E.F., ed. (1998) *Martindale, The Extra Pharmacopoeia*, 13th Ed., London, The Pharmaceutical Press [MicroMedex CD-ROM]
- Ringa, V., Ledésert, B., Gueguen, R., Schiele, F. & Breart, G. (1992) Determinants of hormonal replacement therapy in recently postmenopausal women. *Eur. J. Obstet. Gynecol. reprod. Biol.*, **45**, 193–200
- Risch, H.A. (1996) Estrogen replacement therapy and risk of epithelial ovarian cancer. *Gynecol. Oncol.*, **63**, 254–257
- Risch, H.A. & Howe, G.R. (1994) Menopausal hormone usage and breast cancer in Saskatchewan: A record-linkage cohort study. *Am. J. Epidemiol.*, **139**, 670–683
- Risch, H.A. & Howe, G.R. (1995) Menopausal hormone use and colorectal cancer in Saskatchewan: A record linkage cohort study. *Cancer Epidemiol. Biomarkers Prev.*, **4**, 21–28

- Risch, H.A., Marrett, L.D., Jain, M. & Howe, G.R. (1996) Differences in risk factors for epithelial ovarian cancer by histologic type. Results of a case-control study. *Am. J. Epidemiol.*, **144**, 363–372
- Rodriguez, C., Calle, E.E., Coates, R.J., Miracle-McMahill, H.L., Thun, M.J. & Heath, C.W., Jr (1995) Estrogen replacement therapy and fatal ovarian cancer. *Am. J. Epidemiol.*, **141**, 828–835
- Rohan, T.E. & McMichael, A.J. (1988) Non-contraceptive exogenous oestrogen therapy and breast cancer. *Med. J. Aust.*, **148**, 217–221
- Ron, E., Kleinerman, R.A., Boice, J.D., Jr, LiVolsi, V.A., Flannery, J.T. & Fraumeni, J.F., Jr (1987) A population-based case-control study of thyroid cancer. *J. natl Cancer Inst.*, **79**, 1–12
- Rookus, M.A., van Leeuwen, F.E., for the Netherlands Oral Contraceptives and Breast Cancer Study Group (1994) Oral contraceptives and risk of breast cancer in women aged 20–54 years. *Lancet*, **344**, 844–851
- Ross, R.K., Paganini-Hill, A., Gerkins, V.R., Mack, T.M., Pfeffer, R., Arthur, M. & Henderson, B.E. (1980) A case-control study of menopausal estrogen therapy and breast cancer. *J. Am. med. Assoc.*, **243**, 1635–1639
- Ross, R.K., Paganini-Hill, A., Roy, S., Chao, A. & Henderson, B.E. (1988) Past and present preferred prescribing practices of hormone replacement therapy among Los Angeles gynecologists: Possible implications for public health. *Am. J. public Health*, **78**, 516–519
- Roy, D. & Thomas, R.D. (1994) Catalysis of the redox cycling reactions of estrogens by nuclear enzymes. *Arch. Biochem. Biophys.*, **315**, 310–316
- Roy, D., Kalyanaraman, B. & Liehr, J.G. (1991) Superoxide radical mediated reduction of estrogen quinones to semiquinones and hydroquinones. *Biochem. Pharmacol.*, **42**, 1627–1631
- Rozenbaum, H. (1996) Advantages and disadvantages of estrogen treatment by transdermal or oral administration. *Eur. J. Obstet. Gynecol. reprod. Biol.*, **65**, 33–37
- Rubin, G.L., Peterson, H.B., Lee, N.C., Maes, E.F., Wingo, P.A. & Becker, S. (1990) Estrogen replacement therapy and the risk of endometrial cancer: Remaining controversies. *Am. J. Obstet. Gynecol.*, **162**, 148–154
- Ruoff, W.L. & Dziuk, P.J. (1994a) Absorption and metabolism of estrogens from the stomach and duodenum of pigs. *Domest. Anim. Endocrinol.*, **11**, 197–208
- Ruoff, W.L. & Dziuk, P.J. (1994b) Circulation of estrogens introduced into the rectum or duodenum in pigs. *Domest. Anim. Endocrinol.*, **11**, 383–391
- Rutanen, E.-M. (1997) Biology of the endometrium. In: Wren, B.G., ed., *Progress in the Management of the Menopause*, New York, Parthenon Publishing Group, pp. 217–225
- Ruzycky, A.L. (1996) Effects of 17 $\beta$ -estradiol and progesterone on mitogen-activated protein kinase expression and activity in rat uterine smooth muscle. *Eur. J. Pharmacol.*, **300**, 247–254
- Ruzycky, A.L. & Kulick, A. (1996) Estrogen increases the expression of uterine protein kinase C isozymes in a tissue specific manner. *Eur. J. Pharmacol.*, **313**, 257–263
- Sakamoto, S., Kudo, H., Suzuki, S., Mitamura, T., Sassa, S., Kuwa, K., Chun, Z., Yoshimura, S., Maemura, M., Nakayama, T. & Shinoda, H. (1997) Additional effects of medroxyprogesterone acetate on mammary tumors in oophorectomized, estrogenized, DMBA-treated rats. *Anticancer Res.*, **17**, 4583–4588

- Sakr, S.A., El-Mofty, M.M. & Mohamed, A.M. (1989) Enhancement of hepatic tumors induced by *N*-nitrosodimethylamine in female toads *Bufo regularis* by oestrone. *Arch. Geschwulstforsch.*, **59**, 7–10
- Salamone, L.M., Pressman, A.R., Seeley, D.G. & Cauley, J.A. (1996) Estrogen replacement therapy: A survey of older women's attitudes. *Arch. intern. Med.*, **156**, 1293–1297
- Salmi, T. (1980) Endometrial carcinoma risk factors, with special reference to the use of oestrogens. *Acta endocrinol.*, **Suppl. 233**, 37–43
- Sandberg, A.A. & Slaunwhite, W.R. (1957) Studies on phenolic steroids in humans subjects. II. The metabolic fate and hepatobiliary–enteric circulation of <sup>14</sup>C-estrone and <sup>14</sup>C-estradiol in women. *J. clin. Invest.*, **36**, 1266–1278
- Santner, S.J., Ohlsson-Wilhelm, B. & Santen, R.J. (1993) Estrone sulfate promotes human breast cancer cell replication and nuclear uptake of estradiol in MCF-7 cell cultures. *Int. J. Cancer*, **54**, 119–124
- Sarabia, S.F., Zhu, B.T., Kurosawa, T., Tohma, M. & Liehr, J.G. (1997) Mechanism of cytochrome P450-catalyzed hydroxylation of estrogens. *Chem. Res. Toxicol.*, **10**, 767–771
- Satoh, H., Kajimura, T., Chen, C.-J., Yamada, K., Furuhashi, K. & Nomura, M. (1997) Invasive pituitary tumors in female F344 rats induced by estradiol dipropionate. *Toxicol. Pathol.*, **25**, 462–469
- Schairer, C., Byrne, C., Keyl, P.M., Brinton, L.A., Sturgeon, S.R. & Hoover, R.N. (1994) Menopausal estrogen and estrogen–progestin replacement therapy and risk of breast cancer (United States). *Cancer Causes Control*, **5**, 491–500
- Schairer, C., Adami, H.-O., Hoover, R. & Persson, I. (1997) Cause-specific mortality in women receiving hormone replacement therapy. *Epidemiology*, **8**, 59–65
- Schiff, I., Wentworth, B., Koos, B., Ryan, K.J. & Tulchinsky, D. (1978) Effect of estriol administration on the hypogonadal woman. *Fertil. Steril.*, **30**, 278–282
- Schleyer-Saunders, E. (1973) Hormone replacement therapy for menopausal symptoms (Letter to the Editor). *Lancet*, **ii**, 389
- Schnitzler, R., Foth, J., Degen, G.H. & Metzler, M. (1994) Induction of micronuclei by stilbene-type and steroidal estrogens in Syrian hamster embryo and ovine seminal vesicle cells *in vitro*. *Mutat. Res.*, **311**, 85–93
- Schoonen, W.G.E.J., Joosten, J.W.H. & Kloosterboer, H.J. (1995a) Effects of two classes of progestagens, pregnane and 19-nortestosterone derivatives, on cell growth of human breast tumor cells: I. MCF-7 cell lines. *J. Steroid Biochem. mol. Biol.*, **55**, 423–437
- Schoonen, W.G.E.J., Joosten, J.W.H. & Kloosterboer, H.J. (1995b) Effects of two classes of progestagens, pregnane and 19-nortestosterone derivatives, on cell growth of human breast tumor cells: II. T47D cell lines. *J. Steroid Biochem. mol. Biol.*, **55**, 439–444
- Schulte-Hermann, R., Ochs, H., Bursch, W. & Parzefall, W. (1988) Quantitative structure–activity studies on effects of sixteen different steroids on growth and monooxygenases of rat liver. *Cancer Res.*, **48**, 2462–2468
- Schuppler, J., Damme, J. & Schulte-Hermann, R. (1983) Assay of some endogenous and synthetic sex steroids for tumor-initiating activity in rat liver using the Solt–Faber system. *Carcinogenesis*, **4**, 239–241

- Schuurman, A.G., van den Brandt, P.A. & Goldbohm, R.A. (1995) Exogenous hormone use and the risk of postmenopausal breast cancer: Results from the Netherlands cohort study. *Cancer Causes Control*, **6**, 416–424
- Schwartz, U., Volger, H., Schneller, E., Moltz, L. & Hammerstein, J. (1983) Effects of various replacement oestrogens on hepatic transcortin synthesis in climacteric women. *Acta endocrinol.*, **102**, 103–106
- Setnikar, I., Rovati, L.C., Vens-Cappel, B. & Hilgenstock, C. (1996) Pharmacokinetics of estradiol and of estrone during repeated transdermal or oral administration of estradiol. *Arzneim.-Forsch./Drug Res.*, **46**, 766–773
- Shapiro, S., Kaufman, D.W., Slone, D., Rosenberg, L., Miettinen, O.S., Stolley, P.D., Rosenshein, N.B., Watring, W.G., Leavitt, T. & Knapp, R.C. (1980) Recent and past use of conjugated estrogens in relation to adenocarcinoma of the endometrium. *New Engl. J. Med.*, **303**, 485–489
- Shapiro, S., Kelly, J.P., Rosenberg, L., Kaufman, D.W., Helmrich, S.P., Rosenshein, N.B., Lewis, J.L., Knapp, R.C., Stolley, P.D. & Schottenfeld, D. (1985) Risk of localized and widespread endometrial cancer in relation to recent and discontinued use of conjugated estrogens. *New Engl. J. Med.*, **313**, 969–972
- Sheehan, D.M., Frederik, C.B., Branham, W.S. & Heath, J.E. (1982) Evidence for estradiol promotion of neoplastic lesions in the rat vagina after initiation with *N*-methyl-*N*-nitrosourea. *Carcinogenesis*, **3**, 957–959
- Shen, L., Pisha, E., Huang, Z., Pezzuto, J.M., Krol, E., Alam, Z., van Breemen, R.B. & Bolton, J.L. (1997) Bioreductive activation of catechol estrogen-*ortho*-quinones: Aromatization of the B ring in 4-hydroxyequilenin markedly alters quinoid formation and reactivity. *Carcinogenesis*, **18**, 1093–1101
- Shifren, J.L., Tseng, J.F., Zaloudek, C.J., Ryan, I.P., Meng, Y.G., Ferrara, N., Jaffe, R.B. & Taylor, R.N. (1996) Ovarian steroid regulation of vascular endothelial growth factor in the human endometrium: Implications for angiogenesis during the menstrual cycle and in the pathogenesis of endometriosis. *J. clin. Endocrinol. Metab.*, **81**, 3112–3118
- Shull, J.D., Spady, T.J., Snyder, M.C., Johansson S.L. & Pennington, K.L. (1997) Ovary-intact, but not ovariectomized female ACI rats treated with 17 $\beta$ -estradiol rapidly develop mammary carcinoma. *Carcinogenesis*, **18**, 1595–1601
- Siddle, N.C., Townsend, P.T., Young, O., Minardi, J., King, R.J.B. & Whitehead, M.I. (1982) Dose-dependent effects of synthetic progestins on the biochemistry of the estrogenized postmenopausal endometrium. *Acta. obstet. gynecol. scand.*, **Suppl. 106**, 17–22
- Siegfried, S., Pekonen, F., Nyman, T. & Ämmälä, M. (1995) Expression of mRNA for keratinocyte growth factor and its receptor in human endometrium. *Acta obstet. gynecol. scand.*, **74**, 410–414
- Siiteri, P.K. (1987) Adipose tissue as a source of hormones. *Am. J. clin. Nutr.*, **45**, 277–282
- Sina, J.F., Bean, C.L., Dysart, G.R., Taylor, V.I. & Bradley, M.O. (1983) Evaluation of the alkaline elution/rat hepatocyte assay as a predictor of carcinogenic/mutagenic potential. *Mutat. Res.*, **113**, 357–391
- Sinclair, H.K., Bond, C.M. & Taylor, R.J. (1993) Hormone replacement therapy: A study of women's knowledge and attitudes. *Br. J. gen. Prac.*, **43**, 365–370

- Siskind, V., Schofield, F., Rice, D. & Bain, C. (1989) Breast cancer and breast feeding: Results from an Australian case-control study. *Am. J. Epidemiol.*, **130**, 229–236
- Slikker, W., Hill, D.E. & Young, J.F. (1982) Comparison of the transplacental pharmacokinetics of 17 $\beta$ -estradiol and diethylstilbestrol in the subhuman primate. *J. Pharmacol. exp. Ther.*, **221**, 173–182
- Smith, D.C., Prentice, R., Thompson, D.J. & Herrmann, W.L. (1975) Association of exogenous estrogen and endometrial carcinoma. *New Engl. J. Med.*, **293**, 1164–1167
- Snedeker, S.M. & Diaugustine, R.P. (1996) Hormonal and environmental factors affecting cell proliferation and neoplasia in the mammary gland. In: Huff, J., Boyd, J. & Barrett, J.C., eds, *Cellular and Molecular Mechanisms of Hormonal Carcinogenesis: Environmental Influences*, New York, Wiley-Liss, pp. 211–253
- Spector, T.D. (1989) Use of oestrogen replacement therapy in high risk groups in the United Kingdom. *Br. med. J.*, **299**, 1434–1435
- Spengler, R.F., Clarke, E.A., Woolever, C.A., Newman, A.M. & Osborn, R.W. (1981) Exogenous estrogens and endometrial cancer: A case-control study and assessment of potential biases. *Am. J. Epidemiol.*, **114**, 497–506
- Stadberg, E., Mattsson, L.Å. & Milsom, I. (1997) The prevalence and severity of climacteric symptoms and the use of different treatment regimens in a Swedish population. *Acta obstet. gynecol. scand.*, **76**, 442–448
- Stadel, B.V. & Weiss, N. (1975) Characteristics of menopausal women: A survey of King and Pierce counties in Washington, 1973–1974. *Am. J. Epidemiol.*, **102**, 209–216
- Standeven, M., Criqui, M.H., Klauber, M.R., Gabriel, S. & Barrett-Connor, E. (1986) Correlates of change in postmenopausal estrogen use in a population-based study. *Am. J. Epidemiol.*, **124**, 268–274
- Stanford, J.L., Weiss, N.S., Voigt, L.F., Daling, J.R., Habel, L.A. & Rossing, M.A. (1995) Combined estrogen and progestin hormone replacement therapy in relation to risk of breast cancer in middle-aged women. *J. Am. med. Assoc.*, **274**, 137–142
- Stavraky, K.M., Collins, J.A., Donner, A. & Wells, G.A. (1981) A comparison of estrogen use by women with endometrial cancer, gynecologic disorders, and other illnesses. *Am. J. Obstet. Gynecol.*, **141**, 547–555
- Stenchever, M.A., Jarvis, J.A. & Kreger, N.K. (1969) Effect of selected estrogens and progestins on human chromosomes in vitro. *Obstet. Gynecol.*, **34**, 249–252
- Stern, M.D. (1982) Pharmacology of conjugated oestrogens. *Maturitas*, **4**, 333–339
- Studd, J.W.W. (1976) Hormone implants in the climacteric syndrome. In: Campbell, S., ed., *The Management of the Menopause and the Post-menopausal Years*, Lancaster, MTP Press Ltd, pp. 383–385
- Stumpf, P.G. (1990) Pharmacokinetics of estrogen. *Obstet. Gynecol.*, **75**, 9S–14S
- Sturgis, S.H. (1979) Estrogen use and endometrial cancer (Letter to the Editor). *New Engl. J. Med.*, **300**, 922
- Sumi, C., Yokoro, K. & Matsushima, R. (1984) Effects of 17 $\beta$ -estradiol and diethylstilbestrol on concurrent development of hepatic, mammary, and pituitary tumors in WF rats: Evidence for differential effect on liver. *J. natl Cancer Inst.*, **73**, 1229–1234



- Swenberg, J.A. (1981) Utilization of the alkaline elution assay as a short-term test for chemical carcinogens. In: Stich, H.F. & San, R.H.C., eds, *Short-term Tests for Chemical Carcinogens*, New York, Springer-Verlag, pp. 48–58
- Takahashi, M., Iijima, T., Suzuki, K., Ando-Lu, J., Yoshida, M., Kitamura, T., Nishiyama, K., Miyajima, K. & Maekawa, A. (1996) Rapid and high yield induction of endometrial adenocarcinomas in CD-1 mice by a single intrauterine administration of *N*-ethyl-*N*-nitrosourea combined with chronic 17 $\beta$  estradiol treatment. *Cancer Lett.*, **104**, 7–12
- Talamini, R., La Vecchia, C., Franceschi, S., Colombo, F., DeCarli, A., Grattoni, E., Grigoletto, E. & Tognoni, G. (1985) Reproductive and hormonal factors and breast cancer in a northern Italian population. *Int. J. Epidemiol.*, **14**, 70–74
- Talamini, R., Franceschi, S., Dal Maso, L., Negri, E., Conti, E., Filiberti, R., Montella, M., Nanni, O. & La Vecchia, C. (1998) The influence of reproductive and hormonal factors on the risk of colon and rectal cancer in women. *Eur. J. Cancer*, **34**, 1070–1076
- Tang, M. & Subbiah, M.T.R. (1996) Estrogens protect against hydrogen peroxide and archidonic acid induced DNA damage. *Biochim. biophys. Acta*, **1299**, 155–159
- Taton, G., Servais, P. & Galand, P. (1990) Modulation by estrogen of the incidence of diethylnitrosamine-induced gamma-glutamyltranspeptidase-positive foci in rat liver. *Cancer Lett.*, **55**, 45–51
- Tavani, A., Negri, E. & La Vecchia, C. (1996) Menstrual and reproductive factors and biliary tract cancers. *Eur. J. Cancer Prev.*, **5**, 241–247
- Tavani, A., Braga, C., La Vecchia, C., Negri, E. & Franceschi, S. (1997) Hormone replacement treatment and breast cancer risk: An age-specific analysis. *Cancer Epidemiol. Biomarkers Prev.*, **6**, 11–14
- Telang, N.T., Suto, A., Wong, G.Y., Osborne, M.P. & Bradlow, H.L. (1992) Induction by estrogen metabolite 16 $\alpha$ -hydroxyestrone of genotoxic damage and aberrant proliferation in mouse mammary epithelial cells. *J. natl Cancer Inst.*, **84**, 634–638
- Thomas, D.B., Persing, J.P. & Hutchinson, W.B. (1982) Exogenous oestrogens and other risk factors for breast cancer in women with benign breast diseases. *J. natl Cancer Inst.*, **69**, 1017–1025
- Topo, P., K ster, A., Holte, A., Collins, A., Landgren, B.-M., Hemminki, E. & Uutela, A. (1995) Trends in the use of climacteric and postclimacteric hormones in Nordic countries. *Maturitas*, **22**, 89–95
- Townsend, J. (1998) Hormone replacement therapy: Assessment of present use, costs and trends. *Br. J. gen. Pract.*, **48**, 955–958
- Troisi, R., Schairer, C., Chow, W.-H., Schatzkin, A., Brinton, L.A. & Fraumeni, J.F., Jr (1997) A prospective study of menopausal hormones and risk of colorectal cancer (United States). *Cancer Causes Control*, **8**, 130–138
- Tsutsui, T., Suzuki, N., Fukuda, S., Sato, M., Maizumi, H., McLacklan, J.A. & Barrett, J.C. (1987) 17 $\beta$ -Estradiol-induced cell transformation and aneuploidy of Syrian hamster embryo cells in culture. *Carcinogenesis*, **8**, 1715–1719
- Tsutsui, T., Suzuki, N., Maizumi, H. & Barrett, J.C. (1990) Aneuploidy induction in human fibroblasts: Comparison with results in Syrian hamster fibroblasts. *Mutat. Res.*, **240**, 241–249

- Tsutsui, T., Taguchi, S., Tanaka, Y. & Barrett, C. (1997) 17 $\beta$ -Estradiol, diethylstilbestrol, tamoxifen, toremifene and ICI 164,384 induce morphological transformation and aneuploidy in cultured Syrian hamster embryo cells. *Int. J. Cancer*, **70**, 188–193
- Tzonou, A., Day, N.E., Trichopoulos, D., Walker, A., Saliarakis, M., Papapostolou, M. & Polychronopoulou, A. (1984) The epidemiology of ovarian cancer in Greece: A case-control study. *Eur. J. Cancer clin. Oncol.*, **20**, 1045–1052
- Ueda, M., Fujii, H., Yoshizawa, K., Abe, F. & Ueki, M. (1996) Effects of sex steroids and growth factors on migration and invasion of endometrial adenocarcinoma SNG-M cells *in vitro*. *Jpn. J. Cancer Res.*, **87**, 524–533
- Ursin, G., Aragaki, C.C., Paganini-Hill, A., Siemiatycki, J., Thompson, W.D. & Haile, R.W. (1992) Oral contraceptives and premenopausal bilateral breast cancer: A case-control study. *Epidemiology*, **3**, 414–419
- Vakil, D.V., Morgan, R.W. & Halliday, M. (1983) Exogenous estrogens and development of breast and endometrial cancer. *Cancer Detect. Prev.*, **6**, 415–424
- Vessey, M., Baron, J., Doll, R., McPherson, K. & Yeates, D. (1983) Oral contraceptives and breast cancer: Final report of an epidemiologic study. *Br. J. Cancer*, **47**, 455–62
- Vessey, M.P., McPherson, K., Villard-Mackintosh, L. & Yeates, D. (1989) Oral contraceptives and breast cancer: Latest findings in a large cohort study. *Br. J. Cancer*, **59**, 613–617
- Voigt, L.F., Weiss, N.S., Chu, J., Daling, J.R., McKnight, B. & van Belle, G. (1991) Progestagen supplementation of exogenous oestrogens and risk of endometrial cancer. *Lancet*, **338**, 274–277
- Wang, D.Y., De Stavola, B.L., Bulbrook, R.D., Allen, D.S., Kwa, H.G., Verstraeten, A.A., Moore, J.W., Fentiman, I.S., Chaudary, M., Hayward, J.L. & Gravelle, I.H. (1987) The relationship between blood prolactin levels and risk of breast cancer in premenopausal women. *Eur. J. Cancer clin. Oncol.*, **23**, 1541–1548
- Weinstein, A.L., Mahoney, M.C., Nasca, P.C., Hanson, R.L., Leske, M.C. & Varma, A.O. (1993) Oestrogen replacement therapy and breast cancer risk: A case-control study. *Int. J. Epidemiol.*, **22**, 781–789
- Weiss, N.S., Szekely, D.R., English, D.R. & Schweid, A.I. (1979) Endometrial cancer in relation to patterns of menopausal estrogen use. *J. Am. med. Assoc.*, **242**, 261–264
- Weiss, N.S., Daling, J.R. & Chow, W.H. (1981) Incidence of cancer of the large bowel in women in relation to reproductive and hormonal factors. *J. natl Cancer Inst.*, **67**, 57–60
- Weiss, N.S., Lyon, J.L., Krishnamurthy, S., Dietert, S.E., Liff, J.M. & Daling, J.R. (1982) Non-contraceptive estrogen use and the occurrence of ovarian cancer. *J. natl Cancer Inst.*, **68**, 95–98
- Westerdahl, J., Olsson, H., Måsbäck, A., Ingvar, C. & Jonsson, N. (1996) Risk of malignant melanoma in relation to drug intake, alcohol, smoking and hormonal factors. *Br. J. Cancer*, **73**, 1126–1131
- Wheeler, W.J., Cherry, L.M., Downs, T. & Hsu, T.C. (1986) Mitotic inhibition and aneuploidy induction by naturally occurring and synthetic estrogens in Chinese hamster cells *in vitro*. *Mutat. Res.*, **171**, 31–41
- White, E., Malone, K.E., Weiss, N.S. & Daling, J.R. (1994) Breast cancer among young US women in relation to oral contraceptive use. *J. natl Cancer Inst.*, **86**, 505–514

- Whitehead, M.I., Townsend, P.T., Pryse-Davis, J., Ryder, T.A. & King, R.J.B. (1981) Effects of estrogens and progestins on the biochemistry and morphology of the postmenopausal endometrium. *New Engl. J. Med.*, **305**, 1599–1605
- Whittaker, P.G., Morgan, M.R.A., Dean, P.D.G., Cameron, E.H.D. & Lind, T. (1980) Serum equilin, estrone, and oestradiol levels in postmenopausal women after conjugated equine administration. *Lancet*, **i**, 14–16
- Whittemore, A.S., Harris, R., Itnyre, J. & the Collaborative Ovarian Cancer Group (1992) Characteristics relating to ovarian cancer risk: Collaborative analysis of 12 US case-control studies. II. Invasive epithelial ovarian cancers in white women. *Am. J. Epidemiol.*, **136**, 1184–1203
- WHO Collaborative Study of Neoplasia and Steroid Contraceptives (1990) Breast cancer and combined oral contraceptives: Results from a multinational study. *Br. J. Cancer*, **61**, 110–119
- Wilcox, J.G., Stanczyk, F.Z., Morris, R.S., Gentzschlein, E. & Lobo, R.A. (1996) Biologic effects of  $17\alpha$ -dihydroequilin sulfate. *Fertil. Steril.*, **66**, 748–752
- Williams, C.L. & Stancel, G.M. (1996) Estrogens and progestogens. In: Wonsiewicz, M.J. & McCurdy, P., eds, *Goodman & Gilman's The Pharmacological Basis of Therapeutics*, 9th Ed., New York, McGraw-Hill, pp. 1411–1440
- Willis, D.B., Calle, E.E., Miracle-McMahill, H.L. & Heath, C.W., Jr (1996) Estrogen replacement therapy and risk of fatal breast cancer in a prospective cohort of postmenopausal women in the United States. *Cancer Causes Control*, **7**, 449–457
- Wingo, P.A., Layde, P.M., Lee, N.C., Rubin, G. & Ory, H.W. (1987) The risk of breast cancer in postmenopausal women who have used estrogen replacement therapy. *J. Am. med. Assoc.*, **257**, 209–215
- Wotiz, H.H., Beebe, D.R. & Müller, E. (1984) Effect of estrogens on DMBA induced breast tumors. *J. Steroid Biochem.*, **20**, 1067–1075
- Writing Group for the PEPI Trial (1995) Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. *J. Am. med. Assoc.*, **273**, 199–208 (Published erratum in 1995. *J. Am. med. Assoc.*, **274**, 1676)
- Wu, A.H., Paganini-Hill, A., Ross, R.K. & Henderson, B.E. (1987) Alcohol, physical activity and other risk factors for colorectal cancer: A prospective study. *Br. J. Cancer*, **55**, 687–694
- Wu-Williams, A.H., Lee, M., Whittemore, A.S., Gallagher, R.P., Jiao, D., Zheng, S., Zhou, L., Wang, X., Chen, K., Jung, D., Teh, C.-Z., Ling, C., Xu, J.Y. & Paffenbarger, R.S., Jr (1991) Reproductive factors and colorectal cancer risk among Chinese females. *Cancer Res.*, **51**, 2307–2311
- Wysowski, D.K., Golden, L. & Burke, L. (1995) Use of menopausal estrogens and medroxyprogesterone in the United States, 1982–1992. *Obstet. Gynecol.*, **85**, 6–10
- Xu, L.H., Rinehart, C.A. & Kaufman, D.G. (1995) Estrogen-induced anchorage-independence in human endometrial stromal cells. *Int. J. Cancer*, **62**, 772–776
- Yager, J.D. & Liehr, J.G. (1996) Molecular mechanisms of estrogen carcinogenesis. *Ann. Rev. Pharmacol. Toxicol.*, **36**, 203–32

- Yager, J.D., Campbell, H.A., Longnecker, D.S., Roebuck, B.D. & Benoit, M.C. (1984) Enhancement of hepatocarcinogenesis in female rats by ethinyl estradiol and mestranol but not estradiol. *Cancer Res.*, **44**, 3862–3869
- Yamafuji, K., Iiyama, S. & Shinohara, K. (1971) Mode of action of steroid hormones on deoxyribonucleic acid. *Enzymology*, **40**, 259–264
- Yamamoto, T., Terada, N., Nishizawa, Y. & Petrow, V. (1994) Angiostatic activities of medroxyprogesterone acetate and its analogues. *Int. J. Cancer*, **56**, 393–399
- Yang, C.P., Daling, J.R., Band, P.R., Gallagher, R.P., White, E. & Weiss, N.S. (1992) Noncontraceptive hormone use and risk of breast cancer. *Cancer Causes Control*, **3**, 475–479
- Yood, S.M., Ulcickas Yood, M. & McCarthy, B. (1998) A case-control study of hormone replacement therapy and colorectal cancer (Abstract). *Ann. Epidemiol.*, **8**, 133
- Yu, M.C., Tong, M.J., Govindarajan, S. & Henderson, B.E. (1991) Nonviral risk factors for hepatocellular carcinoma in a low-risk population, the non-Asians of Los Angeles County, California. *J. natl Cancer Inst.*, **83**, 1820–1826
- Yuen, J., Persson, I., Bergkvist, L., Hoover, R., Schairer, C. & Adami, H.O. (1993) Hormone replacement therapy and breast cancer mortality in Swedish women: Results after adjustment for 'healthy drug-user' effect. *Cancer Causes Control*, **4**, 369–374
- Zhu, B.T. & Conney, A.H. (1998) Functional role of estrogen metabolism in target cells: review and perspectives. *Carcinogenesis*, **19**, 1–27
- Ziel, H.K. & Finkle, W.D. (1975) Increased risk of endometrial carcinoma among users of conjugated estrogens. *New Engl. J. Med.*, **293**, 1167–1170